WO2010045015A1 - Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists - Google Patents

Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists Download PDF

Info

Publication number
WO2010045015A1
WO2010045015A1 PCT/US2009/058731 US2009058731W WO2010045015A1 WO 2010045015 A1 WO2010045015 A1 WO 2010045015A1 US 2009058731 W US2009058731 W US 2009058731W WO 2010045015 A1 WO2010045015 A1 WO 2010045015A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
disorder
group
mmol
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/058731
Other languages
French (fr)
Inventor
J. Kent Barbay
Kristi Leonard
Devraj Chakravarty
Brian Christopher Shook
Aihua Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CA2740413A priority Critical patent/CA2740413A1/en
Priority to MX2011003966A priority patent/MX2011003966A/en
Publication of WO2010045015A1 publication Critical patent/WO2010045015A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • This invention relates to a novel arylindenopyrimidine and its therapeutic and prophylactic uses.
  • Disorders treated and/or prevented include neurodegenerative and movement disorders ameliorated by antagonizing Adenosine A2a receptors.
  • Adenosine A2a Receptors Adenosine is a purine nucleotide produced by all metabolically active cells within the body. Adenosine exerts its effects via four subtypes of cell surface receptors (Al, A2a, A2b and A3), which belong to the G protein coupled receptor superfamily (Stiles, G.L. Journal of Biological Chemistry, 1992, 267, 6451). Al and A3 couple to inhibitory G protein, while A2a and A2b couple to stimulatory G protein.
  • A2a receptors are mainly found in the brain, both in neurons and glial cells (highest level in the striatum and nucleus accumbens, moderate to high level in olfactory tubercle, hypothalamus, and hippocampus etc. regions) (Rosin, D. L.; Robeva, A.; Woodard, R. L.; Guyenet, P. G.; Linden, J. Journal of Comparative Neurology, 1998, 401, 163).
  • A2a receptors are found in platelets, neutrophils, vascular smooth muscle and endothelium (Gessi, S.; Varani, K. ; Merighi, S. ; Ongini, E.; Bores, P. A. British Journal of Pharmacology, 2000, 129, 2).
  • the striatum is the main brain region for the regulation of motor activity, particularly through its innervation from dopaminergic neurons originating in the substantial nigra.
  • the striatum is the major target of the dopaminergic neuron degeneration in patients with Parkinson's Disease (PD).
  • A2a receptors are co-localized with dopamine D2 receptors, suggesting an important site for the integration of adenosine and dopamine signaling in the brain (Fink, J. S.; Weaver, D. Ri; Rivkees, S. A.; Peterfreund, R. A.; Pollack, A. E.; Adler, E. M.; Reppert, S. M. Brain Research Molecular Brain Research, 1992,14,186).
  • A2a knockout mice with genetic blockade of A2a function have been found to be less sensitive to motor impairment and neurochemical changes when they were exposed to neurotoxin MPTP (Chen, J. F.; Xu, K.; I Petzer, J. P.; Steal, R.; Xu, Y. H.; Beilstein, M.; Sonsalla, P. K.; Castagnoli, K.; Castagnoli, N., Jr.; Schwarsschild, M. A. Journal of Neuroscience, 2001, 1 21, RCl 43).
  • adenosine A2a receptor blockers may provide a new class of antiparkinsonian agents (Impagnatiello, F.; Bastia, E.; Ongini, E.; Monopoli, A. Emerging Therapeutic Targets, 2000, 4, 635).
  • Antagonists of the A 2 A receptor are potentially useful therapies for the treatment of addiction.
  • Major drugs of abuse opiates, cocaine, ethanol, and the like
  • An A 2A receptor antagonist could be used to treat attention deficit hyperactivity disorder (ADHD) since caffeine (a non selective adenosine antagonist) can be useful for treating ADHD, and there are many interactions between dopamine and adenosine neurons.
  • ADHD attention deficit hyperactivity disorder
  • caffeine a non selective adenosine antagonist
  • Antagonists of the A 2A receptor are potentially useful therapies for the treatment of depression.
  • a 2 A antagonists are known to induce activity in various models of depression including the forced swim and tail suspension tests. The positive response is mediated by dopaminergic transmission and is caused by a prolongation of escape-directed behavior rather than by a motor stimulant effect.
  • Antagonists of the A 2 A receptor are potentially useful therapies for the treatment of anxiety.
  • a 2 A antagonist have been shown to prevent emotional/anxious responses in vivo. Neurobiology of Disease (2007), 28(2) 197-205. SUMMARY OF THE INVENTION
  • Compounds of Formula Z are potent small molecule antagonists of the Adenosine A2a receptor.
  • X is selected from the group consisting of
  • R 1 is heteroaryl which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C ( i_ 4) alkyl, CHF 2 , CF 3 , OCF 3 , cyclopropyl, and OQ 1 .
  • R 2 is heteroaryl wherein said heteroaryl is optionally substituted with Cl, F, Br, OQ 1-
  • R a , R b , and R c are independently H or Q 1-4) alkyl;
  • R d is H, -C(i_4)alkyl, -CH 2 CH 2 OCH 2 CH 2 OCH 3 , -CH 2 CO 2 H, -
  • Compounds of Formula Z are potent small molecule antagonists of the Adenosine A2a receptor.
  • X is selected from the group consisting of
  • R 1 is heteroaryl which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C ( i_ 4) alkyl, CHF 2 , CF 3 , OCF 3 , cyclopropyl, and OC ⁇ _
  • R 2 is heteroaryl wherein said heteroaryl is optionally substituted with Cl, F, Br, OC ( i_
  • R d is H, -C ( i_4)alkyl, -CH 2 CH 2 OCH 2 CH 2 OCH 3 , -CH 2 CO 2 H, -
  • X is selected from the group consisting of
  • R 1 is furyl, oxazolyl, thiazolyl, pyridyl, pyrimadyl, isoxazolyl, pyrrolyl, imidazoyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C (1-4) alkyl, CHF 2 , CF 3 , cyclopropyl, and 0C ( i_ 4) alkyl;
  • R 2 is pyrimadyl, isoxazolyl, pyrrolyl, imidazoyl, furyl, oxazolyl, pyridyl or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, C (M) alkyl, CHF 2 , CF 3 , and OC ( i_ 4) alkyl; and solvates, hydrates,
  • X is selected from the group consisting of
  • R 1 is furyl, oxazolyl, thiazolyl, pyridyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C (1-4) alkyl,
  • R 2 is pyridyl or pyridazyl, either of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, C(i_4)alkyl, CHF 2 , CF3, and OC(i_
  • X is selected from the group consisting of
  • R 1 is furyl, oxazolyl, thiazolyl, pyridyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of CN, CH3, CHF 2 , cyclopropyl, and OCH 3 ;
  • R 2 is pyridyl or pyridazyl, either of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, and OCH 3 ; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
  • X is selected from the group consisting of
  • R 1 is selected from the group consisting of:
  • R >2 is selected from the group consisting of:
  • Another embodiemt of the invention is a compound selected from the group consisting of:
  • This invention further provides a method of treating a subject having a condition ameliorated by antagonizing Adenosine A2a receptors, which comprises administering to the subject a therapeutically effective dose of a compound of Formula Z.
  • This invention further provides a method of preventing a disorder ameliorated by antagonizing Adenosine A2a receptors in a subject, comprising of administering to the subject a prophylactically effective dose of the compound of claim 1 either preceding or subsequent to an event anticipated to cause a disorder ameliorated by antagonizing Adenosine A2a receptors in the subject.
  • Compounds of Formula Z can be isolated and used as free bases. They can also be isolated and used as pharmaceutically acceptable salts.
  • salts include hydrobromic, hydroiodic, hydrochloric, perchloric, sulfuric, maleic, fumaric, malic, tartaric, citric, adipic, benzoic, mandelic, methanesulfonic, hydroethanesulfonic, benzenesulfonic, oxalic, palmoic, 2 naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic and saccharic.
  • This invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula Z and a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, from about 0.01 to about 0.1 M and preferably 0.05 M phosphate buyer or 0.8% saline.
  • Such pharmaceutically acceptable carriers can be aqueous or non-aqueous solutions, suspensions and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, ethanol, alcoholic/aqueous solutions, glycerol, emulsions or suspensions, including saline and buffered media.
  • Oral carriers can be elixirs, syrups, capsules, tablets and the like.
  • the typical solid carrier is an inert substance such as lactose, starch, glucose, methyl- cellulose, magnesium stearate, dicalcium phosphate, mannitol and the like.
  • Parenteral carriers include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils.
  • Intravenous carriers include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose and the like.
  • Preservatives and other additives can also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like. All carriers can be mixed as needed with disintegrants, diluents, granulating agents, lubricants, binders and the like using conventional techniques known in the art.
  • This invention further provides a method of treating a subject having a condition ameliorated by antagonizing Adenosine A2a receptors, which comprises administering to the subject a therapeutically effective dose of a compound of Formula Z.
  • the disorder is a neurodegenerative or movement disorder.
  • disorders treatable by the instant pharmaceutical composition include, without limitation, Parkinson's Disease, Huntington's Disease, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer's Disease, and Senile Dementia.
  • the disorder is Parkinson's disease.
  • the term "subject” includes, without limitation, any animal or artificially modified animal having a disorder ameliorated by antagonizing adenosine A2a receptors.
  • the subject is a human.
  • Administering the instant pharmaceutical composition can be effected or performed using any of the various methods known to those skilled in the art.
  • Compounds of Formula Z can be administered, for example, intravenously, intramuscularly, orally and subcutaneously.
  • the instant pharmaceutical composition is administered orally.
  • administration can comprise giving the subject a plurality of dosages over a suitable period of time. Such administration regimens can be determined according to routine methods.
  • a “therapeutically effective dose” of a pharmaceutical composition is an amount sufficient to stop, reverse or reduce the progression of a disorder.
  • a “prophylactically effective dose” of a pharmaceutical composition is an amount sufficient to prevent a disorder, i.e., eliminate, ameliorate and/or delay the disorder's onset. Methods are known in the art for determining therapeutically and prophylactically effective doses for the instant pharmaceutical composition.
  • the effective dose for administering the pharmaceutical composition to a human for example, can be determined mathematically from the results of animal studies.
  • the therapeutically and/or prophylactically effective dose is a dose sufficient to deliver from about 0.001 mg/kg of body weight to about 200 mg/kg of body weight of a compound of Formula Z. In another embodiment, the therapeutically and/or prophylactically effective dose is a dose sufficient to deliver from about 0.05 mg/kg of body weight to about 50 mg/kg of body weight. More specifically, in one embodiment, oral doses range from about 0.05 mg/kg to about 100 mg/kg daily. In another embodiment, oral doses range from about 0.05 mg/kg to about 50 mg/kg daily, and in a further embodiment, from about 0.05 mg/kg to about 20 mg/kg daily.
  • infusion doses range from about 1.0,ug/kg/min to about 10 mg/kg/min of inhibitor, admixed with a pharmaceutical carrier over a period ranging from about several minutes to about several days.
  • the instant compound can be combined with a pharmaceutical carrier at a drug/carrier ratio of from about 0.001 to about 0.1.
  • the invention also provides a method of treating addiction in a mammal, comprising administering a therapeutically effective dose of a compound of Formula Z.
  • the invention also provides a method of treating ADHD in a mammal, comprising administering a therapeutically effective dose of a compound of Formula Z.
  • the invention also provides a method of treating depression in a mammal, comprising administering a therapeutically effective dose of a compound of Formula Z.
  • the invention also provides a method of treating anxiety in a mammal, comprising administering a therapeutically effective dose of a compound of Formula Z.
  • CiV (where a and b are integers referring to a designated number of carbon atoms) refers to an alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl radical or to the alkyl portion of a radical in which alkyl appears as the prefix root containing from a to b carbon atoms inclusive.
  • Ci_ 4 denotes a radical containing 1, 2, 3 or 4 carbon atoms.
  • alkyl refers to a saturated branched or straight chain monovalent hydrocarbon radical, wherein the radical is derived by the removal of one hydrogen atom from a single carbon atom. Unless specifically indicated (e.g. by the use of a limiting term such as "terminal carbon atom"), substituent variables may be placed on any carbon chain atom.
  • Typical alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl and the like. Examples include Ci_galkyl, C ⁇ alkyl and Ci_ 4 alkyl groups.
  • heteroaryl refers to a radical derived by the removal of one hydrogen atom from a ring carbon atom of a heteroaromatic ring system.
  • Typical heteroaryl radicals include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl, isoindolyl, benzo[ ⁇ ]furyl, benzo[ ⁇ ]thienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthal
  • Scheme 1 illustrates the synthetic routes (Paths 1, 2 and 3) leading to compounds of Formula Z (A, B, C, and D).
  • the aminopyrimidine II is reacted with N-bromosuccinimide (NBS), to give the bromothiophene III.
  • bromothiophene III is reacted with R 2 CH 2 ZnCl or R 2 CH 2 ZnBr, where R 2 is as defined in Formula Z, in the presence of a palladium catalyst to afford compounds of Formula Z, where X is CH 2 (A).
  • bromothiophene III is reacted with di- tert-butyldicarbonate [(BoC) 2 O] in the presence of 4-dimethylamino pyridine (DMAP) to give IV that undergoes a metal-halogen exchange and is reacted with R 2 CHO, where R 2 is as defined in Formula Z to give compounds V that are deprotected to give compounds OH where X is ' ⁇ ⁇ " (B).
  • DMAP 4-dimethylamino pyridine
  • Scheme 2 illustrates the synthetic routes (Paths 1, 2 and 3) leading to compounds of Formula Z (A and B).
  • the aminopyrimidine II is reacted with di-tert-butyldicarbonate [(BoC) 2 O] in the presence of 4-dimethylamino pyridine (DMAP) to give the corresponding protected amine IV.
  • DMAP 4-dimethylamino pyridine
  • the thiophene IV is deprotonated with lithium diisopropylamide (LDA) and reacted with R 2 CHO, where R 2 is as defined in Formula Z, to give an intermediate alcohol IX.
  • IX is deprotected with TFA to give compounds of Formula B.
  • IX is reacted with triethylsilane in TFA to give compounds of Formula A.
  • IX is reacted with acetic anhydride to give the corresponding acetate X that is reduced with samarium iodide (SmI 2 ) followed by TFA deprotection to gives compounds of Formula A.
  • R , R are indepedently selected from H, and CH 3 , or R a is H, and R b is CH 2 CH 3 ;
  • Scheme 3 illustrates the synthetic routes (Paths 1 and 2) leading to compounds of Formula A and alkyl substituted compounds of Formula A.
  • aldehyde XI where R 2 is as defined in Formula Z
  • reaction with malononitrile and elemental sulfur under basic conditions gives the thiophene XII.
  • the thiophene XII is condensed under basic conditions with R ⁇ -CN, where R 1 is as defined in Formula Z, to afford compounds of Formula Z where X is CR a R b and R a and Rb are independently H, Me, or Et.
  • aldehydes that are not commercially available can be synthesized following path 2 using XIII where R 2 is as defined in Formula Z, is reacted with allyl bromide under basic conditions to give XIV.
  • Alkene XIV is dihydroxylated using osmium tetroxide in the presence of NMO to give diol XV.
  • Oxidative cleavage of XV with sodium periodate affords aldehydes XI that can follow the arrows from path 1 to afford compounds of Formula A and alkyl substituted compounds of Formula A.
  • Scheme 4 illustrates the synthetic route to compounds of Formula R ⁇ -CN, where R 1 is a C ( i_ 4) alkyl substituted furan.
  • Scheme 4 also illustrates how any R ⁇ CO 2 CH 3 may be converted into R ⁇ -CN.
  • Bromofuran XVI can react with alkylzinc reagents in the presence of a palladium catalyst to give XVII.
  • Ester XVII (or any R ⁇ CO 2 CH 3 ) is reacted with ammonium hydroxide to give the corresponding amide XVIII. Dehydration of the amide is accomplished using POCl 3 in pyridine to give the desired heterocyclic nitrile R ⁇ CN.
  • Scheme 5 illustrates the synthetic routes (Paths 1, 2 and 3) leading to compounds of Formula Z (E, F, G, and H).
  • bromothiophene III is reacted with R 2 CH 2 CH 2 ZnCl or R 2 CH 2 CH 2 ZnBr, where R 2 is as defined in Formula Z, in the presence of a palladium catalyst to afford compounds of Formula Z, where X is CH 2 CH 2 (E).
  • compounds of Formula F can be reduced by hydrogenation to give compounds of Formula Z, where X is ⁇ ⁇ (E).
  • bromothiophene III is reacted with R 2 CHCHB(OH) 2 , where R 2 is as defined in Formula Z, in the presence of a palladium catalyst to give compounds of Formula Z, where X is ⁇ ⁇ (F).
  • bromothiophene III is reacted with R 2 C(CH 2 )B(OH) 2 , where R 2 is as defined in Formula Z, in the presence of palladium to give compounds of Formula Z (G).
  • Compounds of Formula G are reacted with trimethylsufoxonium
  • Example 1 step a
  • Osmium tetroxide (2.5 wt. % solution in t-BuOH, 4.0 mL, 0.32 mmol) was added to a 0 0 C t-BuOH (30 mL)/water (30 mL) of 2-but-3-enyl-pyrazine (2.1 g, 15.8 mmol) and N- methyl morpholine iV-oxide (2.0 g, 17.4 mmol) and the mixture was allowed to warm to rt overnight. TLC analysis indicated a low level of conversion, so an additional 8 mL of OsO 4 was added and the reaction mixture was stirred for 1 d.
  • Oxazole-2-carboxylic acid ethyl ester (1.6 g, 11.4 mmol) was suspended in concentrated NH 4 OH (32 mL) and stirred vigorously. After 26 h the precipitate was collected by vacuum filtration, affording 1.1 g of the title compound that was used without further purification.
  • Neat POCI3 (1.12 mL, 12.3 mmol) was added to a pyridine solution (17 mL) of oxazole- 2-carboxylic acid amide (982 mg, 8.8 mmol). After 4 h the mixture was cooled to 0 0 C and taken to pH 3 with concentrated aqueous HCl. The aqueous mixture was extracted with Et 2 O and the combined extracts were washed with water then brine, dried (Mg 2 SO 4 ), concentrated and used without further purification to give 478 mg of 5-cyclopropyl- furan-2-carbonitrile. The residue contained water, and was therefore dissolved in CH 2 Cl 2 , dried (Na 2 SO 4 ), and concentrated to give 573 mg of the title compound that was used without further purification.
  • Example 3 step a 3-Pyridin-2-yl-propionaldehyde
  • Example 19 step a 5-Cyclopropyl-furan-2-carboxylic acid methyl ester
  • 5-cyclopropyl-furan-2-carboxylic acid methyl ester (650 mg, 3.9 mmol) was suspended in concentrated NH 4 OH (20 rnL) and stirred vigorously. After 16 h the mixture was diluted with water and the aqueous phase was extracted with EtOAc. The combined organic extracts were washed with water and brine, dried (Na 2 SO 4 ), concentrated and used without further purification to give 550 mg of 5-cyclopropyl-furan-2-carboxylic acid amide.
  • Neat POCI3 (0.48 mL, 5.1 mmol) was added to a pyridine solution (9 mL) of 5- cyclopropyl-furan-2-carboxylic acid amide (550 mg, 3.6 mmol). After 2 h the mixture was cooled to 0 0 C and taken to pH 4.5 with concentrated aqueous HCl. The aqueous mixture was extracted with Et 2 O and the combined extracts were washed with brine, dried (Na 2 SO 4 ), concentrated and used without further purification to give 478 mg of 5- cyclopropyl-furan-2-carbonitrile.
  • Example 22 step a
  • Neat TFA (0.15 mL) was added to a CH 2 Cl 2 solution (0.4 mL) of [6-(hydroxy-phenyl- methyl)-2-(2-methoxy-pyridin-4-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert- butyl ester (40 mg). After 1 h the mixture was concentrated and the resulting solid was partitioned between CH 2 Cl 2 and saturated aqueous NaHCO 3 . The organic phase was separated, dried (Na 2 SO 4 ), and concentrated to provide 37 mg of the title compound.
  • Neat TFA (0.2 mL) was added to a CH 2 Cl 2 solution (0.8 mL) of ⁇ 2-(5-difluoromethyl- furan-2-yl)-6-[(3-fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl ⁇ -bis- carbamic acid tert-butyl ester (42 mg, 0.07 mmol). After 1 h the mixture was concentrated in vacuo and the residue was partitioned between saturated aqueous NaHCO 3 and EtOAc. The layers were separated and the organic layer was dried (Na 2 SO 4 ) and concentrated to give 16 mg of the title compound.
  • Example 24 step a
  • Example 24 step c 2-(5-Difluoromethyl-furan-2-yl)-6-(3-fluoro-pyridin-2-ylmethyl)-thieno[2,3- d] pyrimidin-4-ylamine
  • Neat TFA (0.3 niL) was added to a CH 2 Cl 2 solution (1.2 niL) of [2-(5-Difluoromethyl- furan-2-yl)-6-(3-fluoro-pyridin-2-ylmethyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (58 mg, 0.10 mmol). After 30 min the mixture was concentrated in vacuo and the residue was partitioned between saturated aqueous NaHCOs and EtOAc. The layers were separated and the organic layer was dried (Na 2 SO 4 ) and concentrated to give 37 mg of the title compound.
  • Example 25 step a
  • Neat TFA (0.2 mL) was added to a CH 2 Cl 2 solution (0.8 mL) of [2-(5-difluoromethyl- furan-2-yl)-6-(3-fluoro-pyridine-2-carbonyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (25 mg, 0.04 mmol). After 1 h the mixture was concentrated in vacuo and the residue was partitioned between saturated aqueous NaHCO 3 and EtOAc. The layers were separated and the organic layer was dried (Na 2 SO 4 ) and concentrated to give 16 mg of the title compound.
  • the title compound was prepared using [6-(hydroxy-phenyl-methyl)-2-(2-methoxy- pyridin-4-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 22) in place of [6-[(3-chloro-pyridin-2-yl)-hydroxy- methyl]-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester as described in Example 27.
  • Example 30 l-[4-Amino-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6- yl]-l-(3-fluoro-pyridin-2-yl)-ethanol
  • the title compound was prepared using [6-[(3-bromo-pyridin-2-yl)-hydroxy-methyl]-2- (5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 32) in place of ⁇ 2-(5-difluoromethyl-furan-2- yl)-6-[(3-fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl ⁇ -bis- carbamic acid tert-butyl ester as described in Example 24.
  • the title compound was prepared using [2-(5-difluoromethyl-furan-2-yl)-6-(hydroxy- pyridin-2-yl-methyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 31) in place of ⁇ 2-(5-difluoromethyl-furan-2-yl)-6-[(3- fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl ⁇ -bis-carbamic acid tert-butyl ester as described in Example 24.
  • Example 36 l-[4-Amino-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-6- yl]-l-pyridin-2-yl-ethanol
  • Example 36 step a
  • the title compound was prepared using [2-(5-difluoromethyl-furan-2-yl)-6-(hydroxy- pyridin-2-yl-methyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 31) in place of ⁇ 2-(5-difluoromethyl-furan-2-yl)-6-[(3- fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl ⁇ -bis-carbamic acid tert-butyl ester as described in Example 25.
  • the title compound was prepared using ⁇ 2-(5-difluoromethyl-furan-2-yl)-6-[hydroxy-(3- methoxy-pyridin-2-yl)-methyl]-thieno[2,3-d]pyrimidin-4-yl ⁇ -bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 29) in place of ⁇ 2-(5-difluoromethyl-furan-2- yl)-6-[(3-fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl ⁇ -bis- carbamic acid tert-butyl ester as described in Example 24.
  • Ligand binding assay of adenosine A2a receptor was performed using plasma membrane of HEK293 cells containing human A2a adenosine receptor (PerkinElmer, RB-HA2a) and radioligand [ 3 H]CGS21680 (PerkinElmer, NET 1021). Assay was set up in 96-well polypropylene plate in total volume of 200 ⁇ L by sequentially adding 20 ⁇ Ll :20 diluted membrane, 130 ⁇ Lassay buffer (50 mM Tris-HCl, pH7.4 10 mM MgCl 2 , 1 mM EDTA) containing [ 3 H] CGS21680, 50 ⁇ L diluted compound (4X) or vehicle control in assay buffer.
  • Assay was set up in 96-well polypropylene plate in total volume of 200 ⁇ L by sequentially adding 20 ⁇ Ll :20 diluted membrane, 130 ⁇ Lassay buffer (50 mM Tris-HCl, pH7.4 10 mM M
  • Nonspecific binding was determined by 80 mM NECA. Reaction was carried out at room temperature for 2 hours before filtering through 96-well GF/C filter plate pre-soaked in 50 mM Tris ⁇ Cl, pH7.4 containing 0.3% polyethylenimine. Plates were then washed 5 times with cold 50 mM Tris ⁇ Cl, pH7.4, dried and sealed at the bottom. Microscintillation fluid 30 ⁇ L was added to each well and the top sealed. Plates were counted on Packard Topcount for [ 3 H]. Data was analyzed in Microsoft Excel and GraphPad Prism programs. (Varani, K.; Gessi, S.; Dalpiaz, A.; Borea, P.A. British Journal of Pharmacology, 1996, 117, 1693)
  • Adenosine A2a Receptor Functional Assay (A2A GAL2]_
  • cryopreserved CHO-Kl cells overexpressing the human adenosine A2a receptor and containing a cAMP inducible beta-galactosidase reporter gene were thawed, centrifuged, DMSO containing media removed, and then seeded with fresh culture media into clear 384-well tissue culture treated plates (BD #353961) at a concentration of 1OK cells/well. Prior to assay, these plates were cultured for two days at 37 0 C, 5% CO 2 , 90% Rh. On the day of the functional assay, culture media was removed and replaced with 45uL assay medium (Hams/F-12 Modified (Mediatech # 10-080CV) supplemented w/ 0.1% BSA).
  • Test compounds were diluted and 11 point curves created at a 100Ox concentration in 100% DMSO. Immediately after addition of assay media to the cell plates, 5OnL of the appropriate test compound antagonist or agonist control curves were added to cell plates using a Cartesian Hummingbird. Compound curves were allowed to incubate at room temperature on cell plates for approximately 15 minutes before addition of a 15nM NECA (Sigma E2387) agonist challenge (5uL volume). A control curve of NECA, a DMSO/Media control, and a single dose of Forskolin (Sigma F3917) were also included on each plate. After additions, cell plates were allowed to incubate at 37 0 C, 5% CO 2 , 90% Rh for 5.5 - 6 hours.
  • cryopreserved CHO-Kl cells overexpressing the human adenosine Al receptor and containing a cAMP inducible beta-galactosidase reporter gene were thawed, centrifuged, DMSO containing media removed, and then seeded with fresh culture media into clear 384-well tissue culture treated plates (BD #353961) at a concentration of 1OK cells/well. Prior to assay, these plates were cultured for two days at 37 0 C, 5% CO 2 , 90% Rh. On the day of the functional assay, culture media was removed and replaced with 45uL assay medium (Hams/F-12 Modified (Mediatech # 10-080CV) supplemented w/ 0.1% BSA).
  • Test compounds were diluted and 11 point curves created at a 100Ox concentration in 100% DMSO. Immediately after addition of assay media to the cell plates, 5OnL of the appropriate test compound antagonist or agonist control curves were added to cell plates using a Cartesian Hummingbird. Compound curves were allowed to incubate at room temperature on cell plates for approximately 15 minutes before addition of a 4nM r-PIA (Sigma P4532)/luM Forskolin (Sigma F3917) agonist challenge (5uL volume). A control curve of r-PIA in IuM Forskolin, a DMSO/Media control, and a single dose of Forskolin were also included on each plate.
  • ND indicates that no data was available.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a novel thieno[2,3-d]pyrimidine, Z, and its therapeutic and prophylactic uses, wherein X, R1 and R2 are defined in the specification. Disorders treated and/or prevented include Parkinson's Disease.

Description

HETEROARYL SUBSTITUTED THIENO [2,3-d] P YRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefits of the filing of U.S. Provisional Application No. 61/104,791 filed October 13, 2008. The complete disclosures of the aforementioned related patent applications are hereby incorporated herein by reference for all purposes.
FIELD OF THE INVENTION
This invention relates to a novel arylindenopyrimidine and its therapeutic and prophylactic uses. Disorders treated and/or prevented include neurodegenerative and movement disorders ameliorated by antagonizing Adenosine A2a receptors.
BACKGROUND OF THE INVENTION
Adenosine A2a Receptors Adenosine is a purine nucleotide produced by all metabolically active cells within the body. Adenosine exerts its effects via four subtypes of cell surface receptors (Al, A2a, A2b and A3), which belong to the G protein coupled receptor superfamily (Stiles, G.L. Journal of Biological Chemistry, 1992, 267, 6451). Al and A3 couple to inhibitory G protein, while A2a and A2b couple to stimulatory G protein. A2a receptors are mainly found in the brain, both in neurons and glial cells (highest level in the striatum and nucleus accumbens, moderate to high level in olfactory tubercle, hypothalamus, and hippocampus etc. regions) (Rosin, D. L.; Robeva, A.; Woodard, R. L.; Guyenet, P. G.; Linden, J. Journal of Comparative Neurology, 1998, 401, 163).
In peripheral tissues, A2a receptors are found in platelets, neutrophils, vascular smooth muscle and endothelium (Gessi, S.; Varani, K. ; Merighi, S. ; Ongini, E.; Bores, P. A. British Journal of Pharmacology, 2000, 129, 2). The striatum is the main brain region for the regulation of motor activity, particularly through its innervation from dopaminergic neurons originating in the substantial nigra. The striatum is the major target of the dopaminergic neuron degeneration in patients with Parkinson's Disease (PD). Within the striatum, A2a receptors are co-localized with dopamine D2 receptors, suggesting an important site for the integration of adenosine and dopamine signaling in the brain (Fink, J. S.; Weaver, D. Ri; Rivkees, S. A.; Peterfreund, R. A.; Pollack, A. E.; Adler, E. M.; Reppert, S. M. Brain Research Molecular Brain Research, 1992,14,186).
Neurochemical studies have shown that activation of A2a receptors reduces the binding affinity of D2 agonist to their receptors. This D2R and A2aR receptor-receptorinteraction has been demonstrated instriatal membrane preparations of rats (Ferre, S.; con Euler, G.; Johansson, B.; Fredholm, B. B.; Fuxe, K. Proceedings of the National Academy of Sciences I of the United States of America, 1991, 88, 7238) as well as in fibroblast cell lines after transfected with A2aR and D2R cDNAs (Salim, H. ; Ferre, S.; Dalai, A.; Peterfreund, R. A.; Fuxe, K.; Vincent, J. D.; Lledo, P. M. Journal of Neurochemistry, 2000, 74, 432). In vivo, pharmacological blockade of A2a receptors using A2a antagonist leads to beneficial effects in dopaminergic neurotoxin MPTP(l-methyl-4-pheny-l,2,3, 6- tetrahydropyridine)-induced PC) in various species, including mice, rats, and monkeys (Ikeda, K.; Kurokawa, M.; Aoyana, S.; Kuwana, Y. Journal of Neurochemistry, 2002, 80, 262).
Furthermore, A2a knockout mice with genetic blockade of A2a function have been found to be less sensitive to motor impairment and neurochemical changes when they were exposed to neurotoxin MPTP (Chen, J. F.; Xu, K.; I Petzer, J. P.; Steal, R.; Xu, Y. H.; Beilstein, M.; Sonsalla, P. K.; Castagnoli, K.; Castagnoli, N., Jr.; Schwarsschild, M. A. Journal of Neuroscience, 2001, 1 21, RCl 43).
In humans, the adenosine receptor antagonist theophylline has been found to produce beneficial effects in PD patients (Mally, J.; Stone, T. W. Journal of the Neurological Sciences, 1995, 132, 129). Consistently, recent epidemiological study has shown that high caffeine consumption makes people less likely to develop PD (Ascherio, A.; Zhang, S. M.; Hernan, M. A.; Kawachi, L; Colditz, G. A.; Speizer, F. E.; Willett, W. C. Annals of Neurology, 2001, 50, 56). In summary, adenosine A2a receptor blockers may provide a new class of antiparkinsonian agents (Impagnatiello, F.; Bastia, E.; Ongini, E.; Monopoli, A. Emerging Therapeutic Targets, 2000, 4, 635).
Antagonists of the A2A receptor are potentially useful therapies for the treatment of addiction. Major drugs of abuse (opiates, cocaine, ethanol, and the like) either directly or indirectly modulate dopamine signaling in neurons particularly those found in the nucleus accumbens, which contain high levels OfA2A adenosine receptors. Dependence has been shown to be augmented by the adenosine signaling pathway, and it has been shown that administration of an A2A receptor antagonist redues the craving for addictive substances ("The Critical Role of Adenosine A2A Receptors and Gi βγ Subunits in Alcoholism and Addiction: From Cell Biology to Behavior", by Ivan Diamond and Lina Yao, (The Cell Biology of Addiction, 2006, pp 291-316) and "Adaptations in Adenosine Signaling in Drug Dependence: Therapeutic Implications", by Stephen P. Hack and Macdonald J. Christie, Critical Review in Neurobiology, Vol. 15, 235-274 (2003)). See also Alcoholism: Clinical and Experimental Research (2007), 31(8), 1302-1307.
An A2A receptor antagonist could be used to treat attention deficit hyperactivity disorder (ADHD) since caffeine (a non selective adenosine antagonist) can be useful for treating ADHD, and there are many interactions between dopamine and adenosine neurons. Clinical Genetics (2000), 58(1), 31-40 and references therein.
Antagonists of the A2A receptor are potentially useful therapies for the treatment of depression. A2A antagonists are known to induce activity in various models of depression including the forced swim and tail suspension tests. The positive response is mediated by dopaminergic transmission and is caused by a prolongation of escape-directed behavior rather than by a motor stimulant effect. Neurology (2003), 61(suppl 6) S82-S87.
Antagonists of the A2A receptor are potentially useful therapies for the treatment of anxiety. A2A antagonist have been shown to prevent emotional/anxious responses in vivo. Neurobiology of Disease (2007), 28(2) 197-205. SUMMARY OF THE INVENTION
Compounds of Formula Z are potent small molecule antagonists of the Adenosine A2a receptor.
R2 S^N R1 xΛΛfI
NH2 z
wherein
X is selected from the group consisting of
Figure imgf000005_0001
R1 is heteroaryl which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C(i_4)alkyl, CHF2, CF3, OCF3, cyclopropyl, and OQ1.
4)alkyl;
R2 is heteroaryl wherein said heteroaryl is optionally substituted with Cl, F, Br, OQ1-
4)alkyl, OCF3, OH, Qi_4)alkyl, CHF2, CF3, OCH2CF3, or a ring selected from the group consisting of:
Figure imgf000005_0002
wherein Ra, Rb, and Rc are independently H or Q1-4)alkyl; Rd is H, -C(i_4)alkyl, -CH2CH2OCH2CH2OCH3, -CH2CO2H, -
C(O)C(1_4)alkyl, or -CH2C(O)C(M)alkyl;
and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
DETAILED DESCRIPTION OF THE INVENTION
Compounds of Formula Z are potent small molecule antagonists of the Adenosine A2a receptor.
Figure imgf000006_0001
wherein
X is selected from the group consisting of
Figure imgf000006_0002
R1 is heteroaryl which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C(i_4)alkyl, CHF2, CF3, OCF3, cyclopropyl, and OCα_
4)alkyl;
R2 is heteroaryl wherein said heteroaryl is optionally substituted with Cl, F, Br, OC(i_
4)alkyl, OCF3, OH, C^alkyl, CHF2, CF3, OCH2CF3, or a ring selected from the group consisting of:
Figure imgf000007_0001
wherein Ra, Rb, and Rc are independently H or C(1-4)alkyl;
Rd is H, -C(i_4)alkyl, -CH2CH2OCH2CH2OCH3, -CH2CO2H, -
C(0)C(i_4)alkyl, or -CH2C(O)C(M)alkyl; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
In another embodiment of the invention: X is selected from the group consisting of
Figure imgf000007_0002
R1 is furyl, oxazolyl, thiazolyl, pyridyl, pyrimadyl, isoxazolyl, pyrrolyl, imidazoyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C(1-4)alkyl, CHF2, CF3, cyclopropyl, and 0C(i_4)alkyl; R2 is pyrimadyl, isoxazolyl, pyrrolyl, imidazoyl, furyl, oxazolyl, pyridyl or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, C(M)alkyl, CHF2, CF3, and OC(i_4)alkyl; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
In another embodiment of the invention: X is selected from the group consisting of
OH 0H O
>OX , >5* , .W , N^X , W , and >Jyr . R1 is furyl, oxazolyl, thiazolyl, pyridyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C(1-4)alkyl,
CHF2, CF3, cyclopropyl, and OC(i_4)alkyl;
R2 is pyridyl or pyridazyl, either of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, C(i_4)alkyl, CHF2, CF3, and OC(i_
4)alkyl; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
In another embodiment of the invention: X is selected from the group consisting of
>Of , W , W , \ΛX , W , and \V .
R1 is furyl, oxazolyl, thiazolyl, pyridyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of CN, CH3, CHF2, cyclopropyl, and OCH3;
R2 is pyridyl or pyridazyl, either of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, and OCH3; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
In another embodiment of the invention: X is selected from the group consisting of
OH OH O
>OT ϊά K* \^X ><V , and 3&T .
R1 is selected from the group consisting of:
Figure imgf000008_0001
Figure imgf000008_0002
and
Figure imgf000008_0003
; R >2 is selected from the group consisting of:
Figure imgf000009_0001
and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
Another embodiemt of the invention is a compound selected from the group consisting of:
Figure imgf000009_0002
Figure imgf000010_0001
Figure imgf000011_0001
10
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
and solvates, hydrates, tautomers, and pharmaceutically accceptable salts thereof.
This invention further provides a method of treating a subject having a condition ameliorated by antagonizing Adenosine A2a receptors, which comprises administering to the subject a therapeutically effective dose of a compound of Formula Z.
This invention further provides a method of preventing a disorder ameliorated by antagonizing Adenosine A2a receptors in a subject, comprising of administering to the subject a prophylactically effective dose of the compound of claim 1 either preceding or subsequent to an event anticipated to cause a disorder ameliorated by antagonizing Adenosine A2a receptors in the subject.
Compounds of Formula Z can be isolated and used as free bases. They can also be isolated and used as pharmaceutically acceptable salts.
Examples of such salts include hydrobromic, hydroiodic, hydrochloric, perchloric, sulfuric, maleic, fumaric, malic, tartaric, citric, adipic, benzoic, mandelic, methanesulfonic, hydroethanesulfonic, benzenesulfonic, oxalic, palmoic, 2 naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic and saccharic.
This invention also provides a pharmaceutical composition comprising a compound of Formula Z and a pharmaceutically acceptable carrier.
Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, from about 0.01 to about 0.1 M and preferably 0.05 M phosphate buyer or 0.8% saline. Such pharmaceutically acceptable carriers can be aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, ethanol, alcoholic/aqueous solutions, glycerol, emulsions or suspensions, including saline and buffered media. Oral carriers can be elixirs, syrups, capsules, tablets and the like. The typical solid carrier is an inert substance such as lactose, starch, glucose, methyl- cellulose, magnesium stearate, dicalcium phosphate, mannitol and the like. Parenteral carriers include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous carriers include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose and the like.
Preservatives and other additives can also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like. All carriers can be mixed as needed with disintegrants, diluents, granulating agents, lubricants, binders and the like using conventional techniques known in the art.
This invention further provides a method of treating a subject having a condition ameliorated by antagonizing Adenosine A2a receptors, which comprises administering to the subject a therapeutically effective dose of a compound of Formula Z.
In one embodiment, the disorder is a neurodegenerative or movement disorder. Examples of disorders treatable by the instant pharmaceutical composition include, without limitation, Parkinson's Disease, Huntington's Disease, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer's Disease, and Senile Dementia.
In one preferred embodiment, the disorder is Parkinson's disease.
As used herein, the term "subject" includes, without limitation, any animal or artificially modified animal having a disorder ameliorated by antagonizing adenosine A2a receptors. In a preferred embodiment, the subject is a human. Administering the instant pharmaceutical composition can be effected or performed using any of the various methods known to those skilled in the art. Compounds of Formula Z can be administered, for example, intravenously, intramuscularly, orally and subcutaneously. In the preferred embodiment, the instant pharmaceutical composition is administered orally. Additionally, administration can comprise giving the subject a plurality of dosages over a suitable period of time. Such administration regimens can be determined according to routine methods.
As used herein, a "therapeutically effective dose" of a pharmaceutical composition is an amount sufficient to stop, reverse or reduce the progression of a disorder. A "prophylactically effective dose" of a pharmaceutical composition is an amount sufficient to prevent a disorder, i.e., eliminate, ameliorate and/or delay the disorder's onset. Methods are known in the art for determining therapeutically and prophylactically effective doses for the instant pharmaceutical composition. The effective dose for administering the pharmaceutical composition to a human, for example, can be determined mathematically from the results of animal studies.
In one embodiment, the therapeutically and/or prophylactically effective dose is a dose sufficient to deliver from about 0.001 mg/kg of body weight to about 200 mg/kg of body weight of a compound of Formula Z. In another embodiment, the therapeutically and/or prophylactically effective dose is a dose sufficient to deliver from about 0.05 mg/kg of body weight to about 50 mg/kg of body weight. More specifically, in one embodiment, oral doses range from about 0.05 mg/kg to about 100 mg/kg daily. In another embodiment, oral doses range from about 0.05 mg/kg to about 50 mg/kg daily, and in a further embodiment, from about 0.05 mg/kg to about 20 mg/kg daily. In yet another embodiment, infusion doses range from about 1.0,ug/kg/min to about 10 mg/kg/min of inhibitor, admixed with a pharmaceutical carrier over a period ranging from about several minutes to about several days. In a further embodiment, for topical administration, the instant compound can be combined with a pharmaceutical carrier at a drug/carrier ratio of from about 0.001 to about 0.1. The invention also provides a method of treating addiction in a mammal, comprising administering a therapeutically effective dose of a compound of Formula Z.
The invention also provides a method of treating ADHD in a mammal, comprising administering a therapeutically effective dose of a compound of Formula Z.
The invention also provides a method of treating depression in a mammal, comprising administering a therapeutically effective dose of a compound of Formula Z.
The invention also provides a method of treating anxiety in a mammal, comprising administering a therapeutically effective dose of a compound of Formula Z.
DEFINITIONS:
The term "CeV (where a and b are integers referring to a designated number of carbon atoms) refers to an alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl radical or to the alkyl portion of a radical in which alkyl appears as the prefix root containing from a to b carbon atoms inclusive. For example, Ci_4 denotes a radical containing 1, 2, 3 or 4 carbon atoms.
The term "alkyl," whether used alone or as part of a substituent group, refers to a saturated branched or straight chain monovalent hydrocarbon radical, wherein the radical is derived by the removal of one hydrogen atom from a single carbon atom. Unless specifically indicated (e.g. by the use of a limiting term such as "terminal carbon atom"), substituent variables may be placed on any carbon chain atom. Typical alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl and the like. Examples include Ci_galkyl, C^alkyl and Ci_4alkyl groups.
The term "heteroaryl" refers to a radical derived by the removal of one hydrogen atom from a ring carbon atom of a heteroaromatic ring system. Typical heteroaryl radicals include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl, isoindolyl, benzo[δ]furyl, benzo[δ]thienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl and the like.
ABBREVIATIONS:
Herein and throughout this application, the following abbreviations may be used.
Cy cyclohexyl
DMF dimethylformamide
DMSO dimethylsulfoxide
Et ethyl
EtOAc ethyl acetate
KOtBu potassium tert-butoxidc
Me methyl
NBS N-bromo succinimide
OAc acetate
Pd(dppf)Cl2 [1,1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium (II) py pyridine
THF tetrahydrofuran
Xantphos 9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene
GENERAL SCHEMES:
Compounds of Formula Z can be prepared by methods known to those who are skilled in the art. The following reaction schemes are only meant to represent examples of the invention and are in no way meant to be a limit of the invention.
Scheme 1
Figure imgf000019_0001
Figure imgf000019_0002
/-PrMgCI, R2CHO
PATH S
MeMgCI
Figure imgf000019_0003
Figure imgf000019_0004
TFA TFA TFA
Figure imgf000019_0005
Scheme 1 illustrates the synthetic routes (Paths 1, 2 and 3) leading to compounds of Formula Z (A, B, C, and D). Starting with 2-amino-3-cyanothiophene I and following the path indicated by the arrows, condensation under basic conditions with R^-CN, where R1 is as defined in Formula Z, affords the aminopyrimidine II. The aminopyrimidine II is reacted with N-bromosuccinimide (NBS), to give the bromothiophene III. Following path 1 bromothiophene III is reacted with R2CH2ZnCl or R2CH2ZnBr, where R2 is as defined in Formula Z, in the presence of a palladium catalyst to afford compounds of Formula Z, where X is CH2 (A). Following path 2 bromothiophene III is reacted with di- tert-butyldicarbonate [(BoC)2O] in the presence of 4-dimethylamino pyridine (DMAP) to give IV that undergoes a metal-halogen exchange and is reacted with R2CHO, where R2 is as defined in Formula Z to give compounds V that are deprotected to give compounds OH where X is '^ ^" (B). Following path 3, alcohol V is oxidized with Dess-Martin periodinane to give VI that can be deprotected to give compounds of Formula Z, where X O is '^ ^" (C). Ketones Vl are reacted with methylmagnesium chloride, followed by TFA
mediated BOC removal, to afford compounds of Formula Z, where X is "^ V *0*H (D).
Figure imgf000021_0001
LDA, RXHO
Figure imgf000021_0002
IX
TFA,
1. SmI2 2. TFA Et3SiH L/pATH 2 PATH 1
TFA
Figure imgf000021_0003
A B
Scheme 2 illustrates the synthetic routes (Paths 1, 2 and 3) leading to compounds of Formula Z (A and B). Starting with 2-amino-3cyanothiophene I and following the path indicated by the arrows, condensation under basic conditions with R^-CN, where R1 is as defined in Formula Z, affords the aminopyrimidine IL The aminopyrimidine II is reacted with di-tert-butyldicarbonate [(BoC)2O] in the presence of 4-dimethylamino pyridine (DMAP) to give the corresponding protected amine IV. The thiophene IV is deprotonated with lithium diisopropylamide (LDA) and reacted with R2CHO, where R2 is as defined in Formula Z, to give an intermediate alcohol IX. Following path 1, IX is deprotected with TFA to give compounds of Formula B. Following path 2, IX is reacted with triethylsilane in TFA to give compounds of Formula A. Following path 3, IX is reacted with acetic anhydride to give the corresponding acetate X that is reduced with samarium iodide (SmI2) followed by TFA deprotection to gives compounds of Formula A.
Scheme 3
R'
Figure imgf000022_0001
NaIO4
Figure imgf000022_0002
wherein R , R are indepedently selected from H, and CH3, or Ra is H, and Rb is CH2CH3;
Scheme 3 illustrates the synthetic routes (Paths 1 and 2) leading to compounds of Formula A and alkyl substituted compounds of Formula A. Starting with aldehyde XI, where R2 is as defined in Formula Z, reaction with malononitrile and elemental sulfur under basic conditions gives the thiophene XII. The thiophene XII is condensed under basic conditions with R^-CN, where R1 is as defined in Formula Z, to afford compounds of Formula Z where X is CRaRb and Ra and Rb are independently H, Me, or Et. Alternatively, aldehydes that are not commercially available can be synthesized following path 2 using XIII where R2 is as defined in Formula Z, is reacted with allyl bromide under basic conditions to give XIV. Alkene XIV is dihydroxylated using osmium tetroxide in the presence of NMO to give diol XV. Oxidative cleavage of XV with sodium periodate affords aldehydes XI that can follow the arrows from path 1 to afford compounds of Formula A and alkyl substituted compounds of Formula A. Scheme 4
Figure imgf000023_0001
XVII XVIII
Scheme 4 illustrates the synthetic route to compounds of Formula R^-CN, where R1 is a C(i_4)alkyl substituted furan. Scheme 4 also illustrates how any R^CO2CH3 may be converted into R^-CN. Bromofuran XVI can react with alkylzinc reagents in the presence of a palladium catalyst to give XVII. Ester XVII (or any R^CO2CH3) is reacted with ammonium hydroxide to give the corresponding amide XVIII. Dehydration of the amide is accomplished using POCl3 in pyridine to give the desired heterocyclic nitrile R^CN.
Scheme 5
Figure imgf000023_0002
Scheme 5 illustrates the synthetic routes (Paths 1, 2 and 3) leading to compounds of Formula Z (E, F, G, and H). Following path 1, bromothiophene III is reacted with R2CH2CH2ZnCl or R2CH2CH2ZnBr, where R2 is as defined in Formula Z, in the presence of a palladium catalyst to afford compounds of Formula Z, where X is CH2CH2 (E). Alternatively, compounds of Formula F can be reduced by hydrogenation to give compounds of Formula Z, where X is ^^ ^ (E). Following path 2 bromothiophene III is reacted with R2CHCHB(OH)2, where R2 is as defined in Formula Z, in the presence of a palladium catalyst to give compounds of Formula Z, where X is ^ ^ (F). Following path 3 bromothiophene III is reacted with R2C(CH2)B(OH)2, where R2 is as defined in Formula Z, in the presence of palladium to give compounds of Formula Z
Figure imgf000024_0001
(G). Compounds of Formula G are reacted with trimethylsufoxonium
iodide under basic conditions to afford compounds of Formula Z, where X is '^ ^' (H).
EXAMPLES:
Example 1: 6-(6-Chloro-pyridin-3-ylmethyl)-2-(5-methyl-furan-2-yl)-thieno[2,3- d] pyrimidin-4-ylamine
Example 1: step a
2-(5-Methyl-furan-2-yl)-thieno [2,3-d] pyrimidin-4-ylamine
Figure imgf000024_0002
Solid t-BuOK (904 mg, 8.1 mmol) was added to a dioxane suspension (20 mL) of 2- amino-thiophene-3-carbonitrile (5.0 g, 40.3 mmol) and 5-methyl-furan-2-carbonitrile (4.5 g, 40.3 mmol) and the mixture was immersed into a 130 0C oil bath. After 10 min the flask was removed from the oil bath, diluted with THF, filtered and dry packed onto silica gel. Column chromatography gave 5.8 g of 2-(5-methyl-furan-2-yl)-thieno[2,3- d]pyrimidin-4-ylamine.
Example 1: step b 6-Bromo-2-(5-methyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-ylamine
Figure imgf000025_0001
Solid NBS (4.7 g, 26.4 mmol) was added to a THF solution (100 mL) of 2-(5-methyl- furan-2-yl)-thieno[2,3-d]pyrimidin-4-ylamine (5.8 g, 25.1 mmol). After 2 h the mixture was diluted with EtOAc and washed consecutively with saturated aqueous NaHCOs, 1 M aqueous Na2S2O3, and brine. The organic layer was dried (Na2SO4) and dry packed onto silica gel. Column chromatography gave 6.3 g of 6-bromo-2-(5-methyl-furan-2-yl)- thieno[2,3-d]pyrimidin-4-ylamine.
Example 1: step c
6-(6-Chloro-pyridin-3-ylmethyl)-2-(5-methyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4- ylamine
Figure imgf000025_0002
A 0.5 M THF solution of (6-chloro-3-pyridyl)methylzinc chloride (2.1 mL, 1.06 mmol) was added to a THF solution (3 mL) of 6-bromo-2-(5-methyl-furan-2-yl)-thieno[2,3- d]pyrimidin-4-ylamine (110 mg, 0.35 mmol) and Pd(dppf)Cl2 (29 mg, 0.04 mmol) and the mixture was heated to reflux. After 3 h the mixture was diluted with EtOAc, washed with water then brine, dried (Na2SO4), and dry packed onto silica gel. Column chromatography gave 43 mg of the title compound. 1H NMR (Acetone ,400MHz): δ = 7.31 - 7.37 (m, 4 H), 7.22 - 7.31 (m, 1 H), 7.20 (d, J=I.3 Hz, 1 H), 7.02 (d, J=3.0 Hz, 1 H), 6.72 (br. s., 2 H), 6.15 - 6.20 (m, 1 H), 4.23 (s, 2 H), 2.36 ppm (s, 3 H); MS m/e 322 (M+H).
Example 2: 2-Oxazol-2-yl-6-pyrazin-2-ylmethyl-thieno [2,3-d] pyrimidin-4-ylamine
Example 2: step a 2-But-3-enyl-pyrazine
Figure imgf000026_0001
A 2.5 M hexanes solution of n-BuLi (18.0 mL, 45 mmol) was added to a -78 0C THF solution (60 mL) of t-BuOK (5.1 g, 45 mmol) and diisopropylamine (6.3 mL, 45 mmol). After 5 min at -78 0C the yellow mixture was warmed to -40 0C. Neat methylpyrazine (2.7 mL, 30 mmol) was added and the mixture rapidly turned dark red. After 30 min at - 40 0C the mixture was cooled to -78 0C and neat allyl bromide (7.6 mL, 90 mmol) was added. After 30 min at -78 0C water was added and the mixture was partially concentrated to remove volatile organics. The resulting mixture was extracted with dichloromethane and the combined organics were dried (Na2SO4), concentrated, and purified via column chromatography to give 2.2 g of 2-but-3-enyl-pyrazine.
Example 2: step b 4-Pyrazin-2-yl-butane- 1 ,2-diol
Figure imgf000026_0002
Osmium tetroxide (2.5 wt. % solution in t-BuOH, 4.0 mL, 0.32 mmol) was added to a 0 0C t-BuOH (30 mL)/water (30 mL) of 2-but-3-enyl-pyrazine (2.1 g, 15.8 mmol) and N- methyl morpholine iV-oxide (2.0 g, 17.4 mmol) and the mixture was allowed to warm to rt overnight. TLC analysis indicated a low level of conversion, so an additional 8 mL of OsO4 was added and the reaction mixture was stirred for 1 d. Conversion improved, but was still incomplete by TLC analysis; 0.5 equiv //-methyl morpholine iV-oxide (925 mg) and 1.0 equiv pyridine (1.28 rnL) were added, and the mixture was stirred for 2 h. A solution of 24 g Na2SO3 in 96 rnL water was added, and the mixture was partially concentrated to remove volatile organics. The remaining aqueous solution was saturated with sodium chloride and was exhaustively extracted with ethyl acetate. The organic extracts were dried (Na2SO4), concentrated, and was purified by column chromatography to give 1.7 g of the title compound.
Example 2: step c 3-Pyrazin-2-yl-propionaldehyde
Figure imgf000027_0001
An aqueous solution of sodium periodate (0.65 M, 20 mL, 13 mmol, 1.3 equiv) was added to a suspension of silica gel (20 g) in dichloromethane (160 mL). A CH2Cl2 solution (10 mL) of 4-pyrazin-2-yl-butane-l,2-diol (1.7 g, 10.1 mmol) was then added. After 2 h the resulting white slurry was vacuum filtered and washed with CH2Cl2. The filtrate was dried (Na2SO4) and concentrated to give 1.1 g of the title compound that was used without further purification.
Example 2: step d l-Amino-S-pyrazin-l-ylmethyl-thiophene-S-carbonitrile
Figure imgf000027_0002
Solid elemental sulfur (257 mg, 8.0 mmol) was added to a 0 0C DMF solution (2 mL) of 3-pyrazin-2-yl-propionaldehyde (1.1 g, 8.0 mmol) and Et3N (0.67 mL, 4.8 mmol). After 1 h, the solution was cooled to 0 0C and solid malononitrile (529 mg, 8.0 mmol) was added and stirred overnight. The mixture was partitioned between EtOAc and saturated aqueous sodium chloride, and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried (Na2SO4), concentrated, and purified by column chromatography to give 555 mg of the title compound. 1H NMR (CHLOROFORM-d, 300MHz): δ (ppm) 8.44 - 8.59 (m, 3H), 6.54 (s, IH), 4.73 (br. s., 2H), 4.12 (s, 2H)
Example 2: step e Oxazole-2-carboxylic acid amide
Figure imgf000028_0001
Oxazole-2-carboxylic acid ethyl ester (1.6 g, 11.4 mmol) was suspended in concentrated NH4OH (32 mL) and stirred vigorously. After 26 h the precipitate was collected by vacuum filtration, affording 1.1 g of the title compound that was used without further purification.
Example 2: stepf Oxazole-2-carbonitrile
Figure imgf000028_0002
Neat POCI3 (1.12 mL, 12.3 mmol) was added to a pyridine solution (17 mL) of oxazole- 2-carboxylic acid amide (982 mg, 8.8 mmol). After 4 h the mixture was cooled to 0 0C and taken to pH 3 with concentrated aqueous HCl. The aqueous mixture was extracted with Et2O and the combined extracts were washed with water then brine, dried (Mg2SO4), concentrated and used without further purification to give 478 mg of 5-cyclopropyl- furan-2-carbonitrile. The residue contained water, and was therefore dissolved in CH2Cl2, dried (Na2SO4), and concentrated to give 573 mg of the title compound that was used without further purification.
Example 2: step g 2-Oxazol-2-yl-6-pyrazin-2-ylmethyl-thieno[2,3-d]pyrimidin-4-ylamine
Figure imgf000029_0001
Solid t-BuOK (7 mg, 0.06 mmol) was added to a dioxane suspension (0.20 mL) of 2- amino-5-pyrazin-2-ylmethyl-thiophene-3-carbonitrile (68 mg, 0.32 mmol) and oxazole-2- carbonitrile (33 mg, 0.35 mmol) and the mixture was heated by microwave irradiation (150 0C, 10 min, 300 W). The reaction mixture was diluted with dichloromethane and methanol, dry packed onto silica gel, and purified via column chromatography to give 77 mg of the title compound. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.76 (s, IH), 8.65 (s, IH), 8.59 (s, IH), 8.26 (s, IH), 7.75 (br s, 2H), 7.42 (s, IH), 7.39 (s, IH), 4.47 (s, 2H); MS m/e 311 (M+H).
Example 3: 2-Oxazol-2-yl-6-pyridin-2-ylmethyl-thieno [2,3-d] pyrimidin-4-ylamine hydrochloride
Example 3: step a 3-Pyridin-2-yl-propionaldehyde
Figure imgf000029_0002
A CH2Cl2 solution (9 mL) of DMSO (3.7 mL, 52.5 mmol) was added to a -78 0C CH2Cl2 solution (20 mL) of oxalyl chloride (2.3 mL, 26.2 mmol)). After 10 min at -78 0C a CH2Cl2 solution (20 mL) of 2-pyridinepropanol (3.00 g, 21.9 mmol) was added. After 15 min at -78 0C neat triethylamine (15.2 mL, 109.3 mmol) was added, the mixture was stirred for 5 min at -78 0C, then allowed to warm to room temperature and stirred for an additional 40 min. Water was added to the black suspension and the resulting mixture was extracted with CH2Cl2. The combined organic extracts were dried (Na2SO4), concentrated, and purified by column chromatography to give 1.2 g of the title compound. Example 3: step b 2-Amino-5-pyridin-2-ylmethyl-thiophene-3-carbonitrile
Figure imgf000030_0001
Solid elemental sulfur (239 mg, 7.5 mmol) was added to a 0 0C DMF solution (2 rnL) of 3-pyridin-2-yl-propionaldehyde (1.2 g, 9.0 mmol) and Et3N (0.62 mL, 4.5 mmol). After 50 min, the solution was cooled to 0 0C and solid malononitrile (493 mg, 7.5 mmol) was added and the mixture warmed to rt. After 40 min the mixture was partitioned between EtOAc and water, and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried (Na2SO4), concentrated, and purified by column chromatography to give 540 mg of the title compound. 1H NMR (300 MHz, CHLOROFORM-J) δ ppm 8.56 (d, J=4.1 Hz, 1 H), 7.64 (td, J=7.6, 1.7 Hz, 1 H), 7.13 - 7.24 (m, 2 H), 6.50 (s, 1 H), 4.65 (br. s., 2 H), 4.09 (s, 2 H).
Example 3: step c
2-Oxazol-2-yl-6-pyridin-2-ylmethyl-thieno [2,3-d] pyrimidin-4-ylamine hydrochloride
Figure imgf000030_0002
Solid t-BuOK (9 mg, 0.08 mmol) was added to a dioxane suspension (0.20 mL) of 2- amino-5-pyridin-2-ylmethyl-thiophene-3-carbonitrile (87 mg, 0.40 mmol) and oxazole-2- carbonitrile (46 mg, 0.49 mmol, prepared as an intermeduiate in Example 2) and the mixture was heated by microwave irradiation (130 0C, 10 min, 300 W). The reaction mixture was diluted with dichloromethane and methanol, dry packed onto silica gel, and purified via column chromatography to give 107 mg of the title compound. The free base was dissolved in CH2Cl2 containing a minimal amount of methanol to achieve solution and the solution was added to 1 M HCl in Et2O. The precipitated hydrochloride salt was collected by vacuum filtration to give 112 mg of the title compound. 1H NMR (300 MHz, DMS0-D6) δ ppm 8.89 (d, J=4.9 Hz, 1 H), 8.53 (t, J=I .1 Hz, 1 H), 8.31 (s, 1 H), 7.92 - 8.18 (m, 4 H), 7.51 (s, 1 H), 7.48 (s, IH), 4.80 (s, 2 H); MS m/e 310 (M+H).
Example 4: 6-(l-Methyl-l-pyridin-2-yl-ethyl)-2-oxazol-2-yl-thieno[2,3-d]pyrimidin- 4-ylamine
Example 4: step a 2-(l,l-Dimethyl-but-3-enyl)-pyridine
Figure imgf000031_0001
A 2.5 M hexanes solution of n-BuLi (18.0 mL, 45 mmol) was added to a -78 0C THF solution (60 mL) of t-BuOK (5.1 g, 45 mmol) and diisopropylamine (6.3 mL, 45 mmol). After 5 min at -78 0C the yellow mixture was warmed to -40 0C. After 15 min, neat 2- isopropylpyridine (3.87 mL, 30 mmol) was added and the mixture rapidly turned dark red. After 30 min at -40 0C the mixture was cooled to -78 0C and neat allyl bromide (7.6 mL, 90 mmol) was added. After 30 min at -78 0C water was added and the mixture was partially concentrated to remove volatile organics. The resulting mixture was extracted with dichloromethane and the combined organics were dried (Na2SO4), concentrated, and purified via column chromatography to give 4.3 g of 2-(l,l-dimethyl-but-3-enyl)- pyridine.
Example 4: step b 4-Methyl-4-pyridin-2-yl-pentane- 1 ,2-diol
Figure imgf000031_0002
Osmium tetroxide (2.5 wt. % solution in t-BuOH, 13.4 mL, 1.1 mmol) was added to a 0 0C t-BuOH (40 mL)/water (40 mL) of 2-(l,l-dimethyl-but-3-enyl)-pyridine (3.5 g, 21.4 mmol) and JV-methyl morpholine iV-oxide (2.8 g, 23.6 mmol) and the mixture was allowed to warm to rt. After 3 h solid Na2SO3 (32 g) was added portionwise and the resulting suspension was stirred for 1 h. The mixture was partitioned between water and EtOAc and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried (Na2SO4), concentrated, and was purified by column chromatography to give 3.9 g of the title compound.
Example 4: step c 3-Methyl-3-pyridin-2-yl-butyraldehyde
Figure imgf000032_0001
An aqueous solution of sodium periodate (0.65 M, 20 mL, 13 mmol) was added to a suspension of silica gel (20 g) in dichloromethane (160 mL). A CH2Cl2 solution (10 mL) solution of 4-methyl-4-pyridin-2-yl-pentane-l,2-diol (2.0 g, 10.0 mmol) was then added. After 1.5 h the resulting white slurry was vacuum filtered and washed with CH2Cl2. The filtrate was dried (Na2SO4) and concentrated to give 682 mg of the title compound.
Example 4: step d 2-Amino-5-(l-methyl-l-pyridin-2-yl-ethyl)-thiophene-3-carbonitrile
Figure imgf000032_0002
Solid elemental sulfur (110 mg, 3.4 mmol) was added to a 0 0C DMF solution (1 mL) of 3-methyl-3-pyridin-2-yl-butyraldehyde (671 mg, 4.1 mmol) and Et3N (0.29 mL, 2.1 mmol). After 50 min, the solution was cooled to 0 0C and solid malononitrile (226 mg, 3.4 mmol) was added and stirred overnight. The mixture was partitioned between EtOAc and saturated aqueous sodium chloride, and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried (Na2SO4), concentrated, and purified by column chromatography to give 430 mg of the title compound. 1H NMR (CHLOROFORM-d, 300MHz): 1H NMR (CHLOROFORM-d, 300MHz): δ (ppm) 8.57 (d, J=4.9 Hz, IH), 7.61 (td, J=7.8, 2.1 Hz, IH), 7.25 - 7.28 (m, IH, obscured by CHCl3 peak), 7.24 (dt, J=7.9, 1,1, IH), 7.14 (ddd, J=7.5, 4.9, 1.1 Hz, IH), 6.49 (s, IH), 4.63 (br. s., 2H), 1.73 (s, 6H).
Example 4: step e 6-(l-Methyl-l-pyridin-2-yl-ethyl)-2-oxazol-2-yl-thieno[2,3-d]pyrimidin-4-ylamine
Figure imgf000033_0001
Solid t-BuOK (6 mg, 0.05 mmol) was added to a dioxane suspension (0.20 mL) of 2- amino-5-(l-methyl-l-pyridin-2-yl-ethyl)-thiophene-3-carbonitrile (63 mg, 0.26 mmol) and oxazole-2-carbonitrile (27 mg, 0.28 mmol, prepared as an intermediate in Example 2) and the mixture was heated by microwave irradiation (130 0C, 10 min, 300 W). The reaction mixture was diluted with dichloromethane and methanol, dry packed onto silica gel, and purified via column chromatography to give 44 mg of the title compound. 1H NMR (DMSO-de, 300MHz): δ (ppm) 8.57 (ddd, J=4.7, 1.1, 0.9 Hz, IH), 8.25 (s, IH), 7.69 - 7.80 (m, 3H), 7.53 (s, IH), 7.42 (s, IH), 7.40 (d, J=7.9 Hz, IH), 7.24 - 7.29 (m, IH), 1.83 (s, 6H); MS m/e 338 (M+H).
Example 5: 6-(l-Methyl-l-pyridin-2-yl-ethyl)-2-pyrazin-2-yl-thieno[2,3-d]pyrimidin- 4-ylamine
Figure imgf000033_0002
The title compound was prepared using pyrazinecarbonitrile in place of oxazole-2- carbonitrile as described in Example 4. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 9.45 (d, J=Ll Hz, IH), 8.72 - 8.75 (m, IH), 8.70 (d, J=2.3 Hz, IH), 8.55 - 8.59 (m, IH), 7.76 (td, J= 7.7, 1.8 Hz, IH), 7.68 (br s, 2H), 7.54 (s, IH), 7.40 (d, J=7.9 Hz, IH), 7.27 (dd, J= 7.4, 4.8 Hz, IH), 1.84 (s, 6H); MS m/e 349 (M+H).
Example 6: 2-(5-Methyl-furan-2-yl)-6-pyrazin-2-ylmethyl-thieno[2,3-d]pyrimidin-4- ylamine
Figure imgf000034_0001
The title compound was prepared using 5-methyl-2-furonitrile in place of oxazole-2- carbonitrile as described in Example 2. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.74 (s, IH), 8.63 (s, IH), 8.58 (s, IH), 7.48 (br s, 2H), 7.29 (s, IH), 7.00 (d, J=3.0 Hz, IH), 6.25 (d, J=3.0 Hz, IH), 4.41 (s, 2H), 2.35 (s, 3H); MS m/e 324 (M+H).
Example 7: 2-(4-Methyl-thiazol-2-yl)-6-py razin-2-ylmethyl-thieno [2,3-d] pyrimidin- 4-ylamine
Figure imgf000034_0002
The title compound was prepared using 4-methylthiazole-2-carbonitrile in place of oxazole-2-carbonitrile as described in Example 2. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.75 (s, IH), 8.63 - 8.66 (m, IH), 8.59 (d, J=2.6 Hz, IH), 7.69 (br s, 2H), 7.40 (s, IH), 7.37 (s, IH), 4.45 (s, 2H), 2.43 (s, 3H); MS m/e 341 (M+H).
Example 8: 2-(5-Methyl-furan-2-yl)-6-(l-methyl-l-pyridin-2-yl-ethyl)-thieno[2,3- d] pyrimidin-4-ylamine
Figure imgf000035_0001
The title compound was prepared using 5-methyl-2-furonitrile in place of oxazole-2- carbonitrile as described in Example 4. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.56 (d, J=4.9 Hz, IH), 7.74 (dt, J=7.7, 1.9 Hz, IH), 7.47 (br s, 2H), 7.43 (s, IH), 7.36 (d, J=7.9 Hz, IH), 7.25 (dd, J=7.5, 4.9 Hz, IH), 6.99 (d, J=3.0 Hz, IH), 6.24 (d, J=3.0 Hz, IH), 2.35 (s, 3H), 1.80 (s, 6H); MS m/e 351 (M+H).
Example 9: 2-Oxazol-5-yl-6-pyrazin-2-ylmethyl-thieno [2,3-d] pyrimidin-4-ylamine
Figure imgf000035_0002
The title compound was prepared using oxazole-5-carbonitrile in place of oxazole-2- carbonitrile as described in Example 2. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.74 (s, IH), 8.64 (s, IH), 8.58 (d, J=2.6 Hz, IH), 8.51 (s, IH), 7.73 (s, IH), 7.65 (br s, 2H), 7.34 (s, IH), 4.44 (s, 2H); MS m/e 311 (M+H).
Example 10: (±)-2-(5-Methyl-furan-2-yl)-6-(l-pyridin-2-yl-propyl)-thieno[2,3- d] pyrimidin-4-ylamine hydrochloride
Figure imgf000035_0003
The title compound was prepared using 2-n-propylpyridine and 5-methyl-2-furonitrile in place of 2-isopropylpyridine and oxazole-2-carbonitrile, respectively as described in Example 4. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.77 (d, J=5.3 Hz, IH), 8.25 (t, J=7.5 Hz, IH), 7.81 (d, J=7.9 Hz, IH), 7.65 - 7.73 (m, 2H), 7.49 (d, J=3.0 Hz, IH), 6.42 (d, J=3.4 Hz, IH), 4.68 (t, J=I .5 Hz, IH), 2.41 (s, 3H), 2.14 - 2.31 (m, 2H), 0.91 (t, J=7.2 Hz, 3H); MS m/e 351 (M+H).
Example 11: (±)-2-(4-Methyl-thiazol-2-yl)-6-(l-pyridin-2-yl-propyl)-thieno[2,3- d] pyrimidin-4-ylamine hydrochloride
Figure imgf000036_0001
The title compound was prepared using 2-n-propylpyridine and 4-methylthiazole-2- carbonitrile in place of 2-isopropylpyridine and oxazole-2-carbonitrile, respectively, as described in Example 4. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.75 (d, J=4.9 Hz, IH), 8.20 (t, J=7.5 Hz, IH), 7.78 (d, J=7.5 Hz, IH), 7.61 - 7.69 (m, 2H), 7.57 (s, IH), 4.65 (t, J=7.7 Hz, IH), 2.14 - 2.31 (m, 2H), 0.91 (t, J=7.2 Hz, 3H); MS m/e 368 (M+H).
Example 12: (±)-2-Oxazol-2-yl-6-(l-pyridin-2-yl-propyl)-thieno[2,3-d]pyrimidin-4- ylamine hydrochloride
Figure imgf000036_0002
The title compound was prepared using 2-n-propylpyridine in place of 2- isopropylpyridine as described in Example 4. 1H NMR (DMSO-dβ, 300MHz): δ (ppm) 8.81 (d, J=4.9 Hz, IH), 8.29 - 8.40 (m, 2H), 7.90 (d, J=7.9 Hz, IH), 7.78 (t, J=6.4 Hz, IH), 7.62 (s, IH), 7.47 (s, IH), 4.75 (t, J=7.5 Hz, IH), 2.18 - 2.34 (m, 2H), 0.92 (t, J=7.3 Hz, 3H); MS m/e 338 (M+H).
Example 13: 6-(l-Methyl-l-pyridin-2-yl-ethyl)-2-(4-methyl-thiazol-2-yl)-thieno[2,3- d] pyrimidin-4-ylamine
Figure imgf000037_0001
The title compound was prepared using 4-methylthiazole-2-carbonitrile in place of oxazole-2-carbonitrile as described in Example 4. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.57 (d, J=3.8 Hz, IH), 7.76 (td, J=I.1, 1.9 Hz, IH), 7.67 (br s, 2H), 7.51 (s, IH), 7.39 (t, J=4.0 Hz, 2H), 7.27 (dd, J=I.0, 5.1 Hz, IH), 2.43 (s, 3H), 1.83 (s, 6H); MS m/e 368 (M+H).
Example 14: (+)-2-Oxazol-5-yl-6-(l-pyridin-2-yl-propyl)-thieno[2,3-d]pyrimidin-4- ylamine hydrochloride
Figure imgf000037_0002
The title compound was prepared using 2-n-propylpyridine and oxazole-5-carbonitrile in place of 2-isopropylpyridine and oxazole-2-carbonitrile, respectively, as described in Example 4. 1H NMR (DMSO-d6, 300MHz): δ (ppm) 8.78 (d, J=4.9 Hz, IH), 8.54 (s, IH), 8.28 (t, J=8.1 Hz, IH), 7.67 - 7.90 (m, 4H), 7.53 (s, IH), 4.65 (t, J=7.5 Hz, IH), 2.16 - 2.32 (m, 2H), 0.91 (t, J=7.3 Hz, 3H); MS m/e 338 (M+H).
Example 15: 2-Oxazol-5-yl-6-pyridin-2-ylmethyl-thieno[2,3-d]pyrimidin-4-ylamine
Figure imgf000037_0003
The title compound was prepared using oxazole-5-carbonitrile in place of oxazole-2- carbonitrile as described in Example 3. IH NMR (300 MHz, CHLOROFORM-D) δ ppm 8.59 (d, J=4.1 Hz, 1 H), 8.00 (s, 1 H), 7.82 (s, 1 H), 7.67 (td, J=I.6, 1.7 Hz, 1 H), 7.18 - 7.31 (m, 2 H), 6.93 (s, 1 H), 5.44 (br s, 2 H), 4.37 (s, 2 H); MS m/e 310 (M+H).
Example 16: 2-(5-M ethyl- fur an-2-yl)-6-pyridin-2-ylmethyl-thieno[2,3-d]pyrimidin- 4-ylamine
Figure imgf000038_0001
The title compound was prepared using 5-methyl-2-furonitrile in place of oxazole-2- carbonitrile as described in Example 3. IH NMR (300 MHz, CHLOROFORM-D) δ ppm 8.54 (d, J=3.8 Hz, 1 H), 7.62 (td, J=7.6, 1.7 Hz, 1 H), 7.23 (d, J=7.9 Hz, 1 H), 7.13 - 7.17 (m, 2H), 6.86 (s, 1 H), 6.12 (d, J=2.3 Hz, 1 H), 5.61 (s, 2 H), 4.31 (s, 2 H), 2.41 (s, 3 H); MS m/e 322 (M+H).
Example 17: 2-(4-Methyl-thiazol-2-yl)-6-pyridin-2-ylmethyl-thieno[2,3-d]pyrimidin- 4-ylamine
Figure imgf000038_0002
The title compound was prepared using 4-methylthiazole-2-carbonitrile in place of oxazole-2-carbonitrile as described in Example 3. IH NMR (300 MHz, CHLOROFORM-D) δ ppm 8.59 (d, J=4.1 Hz, 1 H), 7.67 (td, J=I.1, 1.9 Hz, 1 H), 7.17 - 7.29 (m, 2 H), 7.02 (s, 1 H), 6.93 (s, 1 H), 5.46 (br s, 2 H), 4.37 (s, 2 H), 2.56 (s, 3 H); MS m/e 340 (M+H).
Example 18: 2-Oxazol-2-yl-6-pyridin-3-ylmethyl-thieno[2,3-d]pyrimidin-4-ylamine
Figure imgf000039_0001
The title compound was prepared using 3-pyridinepropanol in place of 2- pyridinepropanol as described in Example 3. IH NMR (300 MHz, MeOD) δ ppm 8.55 (d, J=I.9 Hz, 1 H), 8.46 (dd, J=A.1, 1.3 Hz, 1 H), 8.09 (s, 1 H), 7.82 (d, J=7.9 Hz, 1 H), 7.43 (dd, J=I.1, 5.1 Hz, 1 H), 7.40 (s, 1 H), 7.24 (s, 1 H), 4.33 (s, 2 H); MS m/e 310 (M+H).
Example 19: 2-(5-Cyclopropyl-furan-2-yl)-6-pyridin-3-ylmethyl-thieno[2,3- d] pyrimidin-4-ylamine
Example 19: step a 5-Cyclopropyl-furan-2-carboxylic acid methyl ester
Figure imgf000039_0002
Solid cyclopropylboronic acid (575 mg, 6.7 mmol) was added to a toluene (22 mL)/ water (1.1 mL) solution of 5-bromo-furan-2-carboxylic acid methyl ester (980 mg, 4.8 mmol), Pd(OAc)2 (54 mg, 0.2 mmol), P(Cy)3 (135 mg, 0.5 mmol), and K3PO4 (3.6 g, 16.8 mmol). The resulting mixture was heated to 90 0C. After 5 h the mixture was cooled, filtered and extracted with EtOAc. The combined organic extracts were washed with water and brine, dried (Na2SO4), concentrated and purified via column chromatography to give 650 mg of 5-cyclopropyl-furan-2-carboxylic acid methyl ester.
Example 19: step b 5-Cyclopropyl-furan-2-carboxylic acid amide
Figure imgf000040_0001
5-cyclopropyl-furan-2-carboxylic acid methyl ester (650 mg, 3.9 mmol) was suspended in concentrated NH4OH (20 rnL) and stirred vigorously. After 16 h the mixture was diluted with water and the aqueous phase was extracted with EtOAc. The combined organic extracts were washed with water and brine, dried (Na2SO4), concentrated and used without further purification to give 550 mg of 5-cyclopropyl-furan-2-carboxylic acid amide.
Example 19: step c S-Cyclopropyl-furan-l-carbonitrile
Figure imgf000040_0002
Neat POCI3 (0.48 mL, 5.1 mmol) was added to a pyridine solution (9 mL) of 5- cyclopropyl-furan-2-carboxylic acid amide (550 mg, 3.6 mmol). After 2 h the mixture was cooled to 0 0C and taken to pH 4.5 with concentrated aqueous HCl. The aqueous mixture was extracted with Et2O and the combined extracts were washed with brine, dried (Na2SO4), concentrated and used without further purification to give 478 mg of 5- cyclopropyl-furan-2-carbonitrile.
Example 19: step d
2-(5-Cyclopropyl-furan-2-yl)-6-pyridin-3-ylmethyl-thieno[2,3-d]pyrimidin-4- ylamine
Figure imgf000040_0003
The title compound was prepared using 3-pyridinepropanol and 5-cyclopropyl-furan-2- carbonitrile in place of 2-pyridinepropanol and oxazole-2-carbonitrile, respectively as described in Example 3. 1H NMR (DMSO-d6 , 300MHz): δ = 8.57 (d, J=I.9 Hz, 1 H), 8.49 (dd, J=4.9, 1.5 Hz, 1 H), 7.68 - 7.77 (m, 1 H), 7.45 (s, 1 H), 7.23 (s, 1 H), 6.99 (d, J=3.4 Hz, 1 H), 6.20 (d, J=3.4 Hz, 1 H), 4.24 (s, 2 H), 3.33 (s, 2 H), 2.01 (s, 1 H), 0.89 - 0.99 (m, 2 H), 0.71 - 0.80 ppm (m, 2 H); MS m/e 349 (M+H).
Example 20: 6-Benzyl-2-(5-cyclopropyl-furan-2-yl)-thieno [2,3-d] pyrimidin-4- ylamine hydrochloride
Figure imgf000041_0001
The title compound was prepared using 5-cyclopropyl-furan-2-carbonitrile in place of and oxazole-2-carbonitrile as described in Example 3. 1H NMR (DMSO-dβ, 300MHz): δ = 8.84 (br. s., 1 H), 8.38 (br. s., 1 H), 7.87 (d, J=8.3 Hz, 2 H), 7.51 (s, 1 H), 7.39 - 7.44 (m, 1 H), 6.40 (d, J=3.0 Hz, 1 H), 4.69 (s, 2 H), 2.08 (t, J=5.1 Hz, 1 H), 1.24 (br. s., 2 H), 0.86 ppm (s, 2 H); MS m/e 349 (M+H).
Example 21: 6-(4-Amino-6-pyridin-3-ylmethyl-thieno [2,3-d] pyrimidin-2-yl)- pyridine-2-carbonitrile
Figure imgf000041_0002
The title compound was prepared using 3-pyridinepropanol and pyridine-2,6- dicarbonitrile in place of 2-pyridinepropanol and oxazole-2-carbonitrile, respectively as described in Example 3. 1H NMR (CHLOROFORM-d, 300MHz): δ = 8.02 (d, J=6.8 Hz, 2 H), 7.45 - 7.71 (m, 4 H), 7.19 (s, 1 H), 6.99 (dd, J=SJ, 1.9 Hz, 1 H), 3.83 (s, 2 H), 3.3 ppm (s, 2 H); MS m/e 345 (M+H). Example 22: [4-Amino-2-(2-methoxy-pyridin-4-yl)-thieno [2,3-d] pyrimidin-6-yl]- phenyl-methanol
Example 22: step a
2-(2-Methoxy-pyridin-4-yl)-thieno [2,3-d] pyrimidin-4-ylamine
Figure imgf000042_0001
The title compound was prepared using 2-methoxy-isonicotinonitrile and in place of 5- methyl-furan-2-carbonitrile as described in Example 1.
Example 22: step b
[2-(2-Methoxy-pyridin-4-yl)-thieno [2,3-d] pyrimidin-4-yl] -bis-carbamic acid tert- butyl ester
Figure imgf000042_0002
Solid DMAP (100 mg, 0.82 mmol) was added to a THF solution (20 mL) of 2-(2- methoxy-pyridin-4-yl)-thieno[2,3-d]pyrimidin-4-ylamine (2.0 g, 8.0 mmol) and (BoC)2O (4.4 g, 20.2 mmol). After 2 h the mixture was concentrated in vacuo, and the resulting solid was diluted with CH2Cl2, filtered, and the filtrate was concentrated and purified by column chromatography to give 3.O g of the title compound.
Example 22: step c
[6-(Hydroxy-pyridin-2-yl-methyl)-2-(2-methoxy-pyridin-4-yl)-thieno[2,3- d]pyrimidin-4-yl] -bis-carbamic acid tert-butyl ester
Figure imgf000043_0001
A 1.8 M LDA solution (0.54 niL, 0.97 mmol) was added to a -78 0C THF solution (3.5 niL) of [2-(2-methoxy-pyridin-4-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert- butyl ester (400 mg, 0.87 mmol). After 8 min, neat pyridine -2-carbaldehyde (140 mg, 1.31 mmol) was added and the mixture was allowed to warm to -20 0C over 40 min. Saturated aqueous NH4Cl was added and the layers were separated. The aqueous layer was extracted with CH2Cl2 and the combined organics were dried (Na2SO4), concentrated, and purified by column chromatography to give 200 mg of the title compound.
Example 22: step d
[4-Amino-2-(2-methoxy-pyridin-4-yl)-thieno [2,3-d] pyrimidin-6-yl] -phenyl-methanol
Figure imgf000043_0002
Neat TFA (0.15 mL) was added to a CH2Cl2 solution (0.4 mL) of [6-(hydroxy-phenyl- methyl)-2-(2-methoxy-pyridin-4-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert- butyl ester (40 mg). After 1 h the mixture was concentrated and the resulting solid was partitioned between CH2Cl2 and saturated aqueous NaHCO3. The organic phase was separated, dried (Na2SO4), and concentrated to provide 37 mg of the title compound. 1H NMR (300MHz, Acetone-d6) δ = 8.56 (d, J= 4.9 Hz, 1 H), 8.22 (d, J= 5.3 Hz, 1 H), 7.79 - 7.92 (m, 2 H), 7.62 - 7.72 (m, 2 H), 7.49 (s, 1 H), 7.32 (dd, J = 4.9, 7.5 Hz, 1 H), 6.99 (br. s., 2 H), 6.13 (d, J = 4.5 Hz, 1 H), 5.92 (br. s., 1 H), 3.92 (s, 3 H); MS m/e 366 (M+H). Example 23: [4- Amino-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6-yl] - (3-fluoro-pyridin-2-yl)-methanol
Example 23: step a 5-Difluoromethyl-furan-2-carbonitrile
NC^/°\^CHF2
To a solution Of Et2NSF3 (2.8 mL, 21.4 mmol) and CH2Cl2 (10 mL) at 4 0C was added a solution of 5-formyl-furan-2-carbonitrile (2.44 g, 20.2 mmol; W. Hoyle and G. P. Roberts, J. Med. Chem. 1973, 16, 709) in CH2Cl2 (10 mL). After 30 min at 4 0C, saturated aqueous NaHCO3 was added, the layers were separated and the aqueous layer was extracted with CH2Cl2. The combined organics were dried (Na2SO4) and concentrated to give 2.15 g of 5-difluoromethyl-furan-2-carbonitrile that was used without further purification.
Example 23: step b 2-(5-Difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-ylamine
Figure imgf000044_0001
Solid t-BuONa (280 mg, 2.9 mmol) was added to a dioxane solution (8 mL) of 5- difluoromethyl-furan-2-carbonitrile (2.1 g, 14.7 mmol) and 2-amino-thiophene-3- carbonitrile (1.8 g, 14.7 mmol) and the mixture immediately became very hot, some solid was formed, and stirring became difficult. An additional 4 mL of dioxane was added and the mixture was stirred. After 1.5 h the mixture was diluted with THF and dry packed onto silica gel. Column chromatography gave 2.9 g of the title compound.
Example 23: step c 6-Bromo-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-ylamine
Figure imgf000045_0001
Solid NBS (3.0 g, 16.6 mmol) was added to a THF solution (110 mL) of 2-(5- difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-ylamine (3.1 g, 11.8 mmol). After 2.5 h the mixture was dry packed onto silica gel. Column chromatography gave 4.8 g of the title compound.
Example 23: step d
[6-Bromo-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-4-yl] -bis- carbamic acid tert-butyl ester
Figure imgf000045_0002
Solid DMAP (170 mg, 1.39 mmol) was added to a THF solution (130 mL) of 6-bromo-2- (5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-ylamine (4.8 g, 13.9 mmol) and BoC2O (7.93 g, 36.4 mmol). After 40 min the mixture was concentrated in vacuo and purified via column chromatography to afford 4.6 g of the title compound.
Example 23: step e
{2-(5-Difluoromethyl-furan-2-yl)-6-[(3-fluoro-pyridin-2-yl)-hydroxy-methyl]- thieno [2,3-d] pyrimidin-4-yl}-bis-carbamic acid tert-butyl ester
Figure imgf000045_0003
A 1.0 M THF solution of /-PrMgCl LiCl (0.70 mL, 0.70 mmol) was added to a -78 0C THF solution (1 mL) of [6-bromo-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3- d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (308 mg, 0.56 mmol). After 1 h at - 78 0C a THF solution (0.8 mL) of 3-fluoro-pyridine-2-carbaldehyde (106 mg, 0.85 mmol) was added and the reaction mixture was warmed to -15 0C. After ~ 40 min, saturated aqueous NH4Cl was added and the aqueous phase was extracted with CH2Cl2. The combined organics were dried (Na2SO4), concentrated, and purified via column chromatography to give 183 mg of the title compound.
Example 23: step f
[4-Amino-2-(5-difluor omethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6-yl] -(3-fluoro- pyridin-2-yl)-methanol
Figure imgf000046_0001
Neat TFA (0.2 mL) was added to a CH2Cl2 solution (0.8 mL) of {2-(5-difluoromethyl- furan-2-yl)-6-[(3-fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl}-bis- carbamic acid tert-butyl ester (42 mg, 0.07 mmol). After 1 h the mixture was concentrated in vacuo and the residue was partitioned between saturated aqueous NaHCO3 and EtOAc. The layers were separated and the organic layer was dried (Na2SO4) and concentrated to give 16 mg of the title compound. 1H NMR (300MHz, Acetone-d6) δ = 8.49 (d, J= 4.5 Hz, 1 H), 7.62 - 7.75 (m, 1 H), 7.51 (dt, J= 4.3, 8.4 Hz, 1 H), 7.40 (s, 1 H), 7.14 - 7.25 (m, 1 H), 7.00 (t, J = 53.7 Hz, 1 H), 6.89 - 7.09 (m, 3 H), 6.33 (s, 1 H), 5.63 (br. s., 1 H); MS m/e 393 (M+H).
Example 24: 2-(5-Difluoromethyl-furan-2-yl)-6-(3-fluoro-pyridin-2-ylmethyl)- thieno [2,3-d] pyrimidin-4-ylamine
Example 24: step a
Acetic acid [4-tert-butoxycarbonylamino-2-(5-difluoromethyl-furan-2-yl)- thieno [2,3-d] pyrimidin-6-yl] -(3-fluoro-pyridin-2-yl)-methyl ester
Figure imgf000047_0001
Solid DMAP (5 mg, 0.04 mmol) was added to a CH2Cl2 solution (1 niL) of {2-(5- difluoromethyl-furan-2-yl)-6-[(3-fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3- d]pyrimidin-4-yl}-bis-carbamic acid tert-butyl ester (120 mg, 0.20 mmol, an intermediate prepared in Example 23), Ac2O (50 μL, 0.53 mmol) and pyridine (0.1 mL). After 5 h the mixture was concentrated and purified by flash chromatography to give 110 mg of the title compound.
Example 24: step b
[2-(5-Difluoromethyl-furan-2-yl)-6-(3-fluoro-pyridin-2-ylmethyl)-thieno[2,3- d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester
Figure imgf000047_0002
A THF solution (1.5 mL) of acetic acid [4-tert-butoxycarbonylamino-2-(5- difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-6-yl]-(3-fluoro-pyridin-2-yl)-methyl ester (100 mg, 0.16 mmol) was purged with N2 for ~ 6 min, t-BuOH (23 μL, 0.24 mmol) was added followed by a 0.1 M THF solution of SmI2 (6.4 mL, 0.64 mmol). After stirring of the blue mixture for 25 min, the blue color changed to yellow and an additional 6.4 mL of the 0.1 M THF solution of SmI2 was added. After 1 h saturated aqueous NH4Cl was added and the organic layer was separated. The aqueous layer was extracted with EtOAc and the combined organics were dried (Na2SO4), concentrated, and purified by column chromatography to yield 58 mg of the title compound.
Example 24: step c 2-(5-Difluoromethyl-furan-2-yl)-6-(3-fluoro-pyridin-2-ylmethyl)-thieno[2,3- d] pyrimidin-4-ylamine
Figure imgf000048_0001
Neat TFA (0.3 niL) was added to a CH2Cl2 solution (1.2 niL) of [2-(5-Difluoromethyl- furan-2-yl)-6-(3-fluoro-pyridin-2-ylmethyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (58 mg, 0.10 mmol). After 30 min the mixture was concentrated in vacuo and the residue was partitioned between saturated aqueous NaHCOs and EtOAc. The layers were separated and the organic layer was dried (Na2SO4) and concentrated to give 37 mg of the title compound. 1U NMR (300MHz, Acetone-d6) δ = 8.41 (d, J = 4.9 Hz, 1 H), 7.62 (t, J = 9.2 Hz, 1 H), 7.40 (dt, J = 4.4, 8.5 Hz, 1 H), 7.33 (s, 1 H), 7.14 - 7.23 (m, 1 H), 7.00 (t, J = 53.9 Hz, 1 H), 6.87 - 6.98 (m, 3 H), 4.45 (d, J = 1.9 Hz, 2 H); MS m/e 377 (M+H).
Example 25: [4-Amino-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-6-yl]- (3-fluoro-pyridin-2-yl)-methanone
Example 25: step a
[2-(5-Difluoromethyl-furan-2-yl)-6-(3-fluoro-pyridine-2-carbonyl)-thieno[2,3- d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester
Figure imgf000048_0002
Solid Dess-Martin periodinane (90 mg, 0.21 mmol) was added to a CH2Cl2 solution (1.5 mL) of {2-(5-difluoromethyl-furan-2-yl)-6- [(3 -fluoro-pyridin-2-yl)-hydroxy-methyl] - thieno[2,3-d]pyrimidin-4-yl}-bis-carbamic acid tert-butyl ester (94 mg, 0.16 mmol, an intermediate prepared in Example 23). After 1 h and saturated aqueous NaHCO3 and saturated aqueous Na2S2O3 were added. The mixture was stirred vigorously for ~ 15 min and the aqueous phase was extracted with CH2Cl2. The combined extracts were dried (Na2SO4), concentrated, and purified via column chromatography to yield 71 mg of the title compound.
Example 25: step b
[4-Amino-2-(5-difluor omethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6-yl] -
(3-fluoro-pyridin-2-yl)-methanone
Figure imgf000049_0001
Neat TFA (0.2 mL) was added to a CH2Cl2 solution (0.8 mL) of [2-(5-difluoromethyl- furan-2-yl)-6-(3-fluoro-pyridine-2-carbonyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (25 mg, 0.04 mmol). After 1 h the mixture was concentrated in vacuo and the residue was partitioned between saturated aqueous NaHCO3 and EtOAc. The layers were separated and the organic layer was dried (Na2SO4) and concentrated to give 16 mg of the title compound. 1H NMR (300MHz, DMSO-d6) δ = 8.63 (d, J = 4.5 Hz, 1 H), 8.46 (s, 1 H), 8.20 (br. s., 2 H), 8.01 (t, J = 9.6 Hz, 1 H), 7.81 (m, 1 H), 7.30 (d, J = 3.4 Hz, 1 H), 7.17 (t, J= 52.9 Hz , 1 H), 7.06 - 7.04 (m, 1 H); MS m/e 391 (M+H).
Example 26: [4- Amino-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6-yl] - (3-chloro-pyridin-2-yl)-methanol
Figure imgf000049_0002
The title compound was prepared using 3-chloro-pyridine-2-carbaldehyde in place of 3- fluoro-pyridine-2-carbaldehyde as described in example 23. 1H NMR (300MHz, Acetone-de) δ = 8.63 (d, J= 4.5 Hz, 1 H), 7.95 (d, J= 8.3 Hz, 1 H), 7.48 (dd, J= 4.7, 7.7 Hz, 1 H), 7.40 (s, 1 H), 7.15 - 7.25 (m, 1 H), 6.91 - 7.12 (m, 3 H), 7.00 (t, J= 53.7 Hz, 1 H), 6.37 (d, J= 6.8 Hz, 1 H), 5.51 - 5.74 (m, 1 H); MS m/e 409/411 (M+H).
Example 27: 6-(3-Chloro-pyridin-2-ylmethyl)-2-(5-difluoromethyl-furan-2-yl)- thieno [2,3-d] pyrimidin-4-ylamine
Figure imgf000050_0001
[6-[(3-Chloro-pyridin-2-yl)-hydroxy-methyl]-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3- d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (36 mg, 0.06 mmol, an intermediate prepared in Example 26), Et3SiH (0.3 mL), and TFA (0.4 rnL) were combined and heated at 80 0C in the microwave for 1.5 h. The mixture was concentrated in vacuo, and the residue was partitioned between EtOAc and saturated aqueous NaHCO3. The organic phase was dried (Na2SO4), concentrated, and purified by preparative thin layer chromatography to yield 15 mg of the title compound. 1H NMR (300MHz, Acetone-dβ) δ = 8.46 - 8.58 (m, 1 H), 7.88 (dd, J = 1.5, 7.9 Hz, 1 H), 7.36 (dd, J = 4.7, 8.1 Hz, 1 H), 7.32 (s, 1 H), 7.14 - 7.22 (m, 1 H), 7.00 (t, J = 53.9 Hz, 1 H), 6.86 - 6.98 (m, 3 H), 4.54 (s, 2 H); MS m/e 393/395 (M+H).
Example 28: 2-(2-Methoxy-pyridin-4-yl)-6-pyridin-2-ylmethyl-thieno [2,3- d] pyrimidin-4-ylamine
Figure imgf000050_0002
The title compound was prepared using [6-(hydroxy-phenyl-methyl)-2-(2-methoxy- pyridin-4-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 22) in place of [6-[(3-chloro-pyridin-2-yl)-hydroxy- methyl]-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester as described in Example 27. 1H NMR (300MHz, Acetone-d6) δ = 8.56 (d, J= 4.5 Hz, 1 H), 8.22 (d, J= 5.3 Hz, 1 H), 7.87 (d, J= 5.7 Hz, 1 H), 7.76 (m, 1 H), 7.69 (s, 1 H), 7.41 (d, J = 7.9 Hz, 1 H), 7.35 (s, 1 H), 7.21 - 7.31 (m, 1 H), 6.93 (br. s., 2 H), 4.40 (s, 2 H), 3.93 (s, 3 H); MS m/e 350 (M+H).
Example 29: [4- Amino-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6-yl] - (3-methoxy-pyridin-2-yl)-methanol
Figure imgf000051_0001
The title compound was prepared using 3-methoxy-pyridine-2-carbaldehyde in place of 3-fluoro-pyridine-2-carbaldehyde as described in example 23. 1H NMR (300MHz, Acetone-de) δ = 8.20 (d, J= 4.1 Hz, 1 H), 7.51 (d, J= 8.3 Hz, 1 H), 7.33 - 7.46 (m, 2 H), 7.08 - 7.22 (m, 1 H), 6.99 (t, J = 53.5 Hz, 1 H), 6.85 - 6.98 (m, 2 H), 6.22 (s, 1 H), 3.92 (s, 3 H); MS m/e 405 (M+H).
Example 30: l-[4-Amino-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6- yl]-l-(3-fluoro-pyridin-2-yl)-ethanol
Figure imgf000051_0002
A 3.0 M THF solution of MeMgCl (0.04 mL, 0.12 mmol) was added to a 4 0C THF solution (1 mL) of [2-(5-difluoromethyl-furan-2-yl)-6-(3-fluoro-pyridine-2-carbonyl)- thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (44 mg, 0.07 mmol, an intermediate prepared in Example 25). After 30 min at 4 0C the mixture was warmed to rt. After 1 h at rt an additional 0.04 mL of the 3.0 M THF solution of MeMgCl was added and the mixture was stirred overnight. Saturated aqueous NH4Cl was added and the aqueous phase was extracted with CH2Cl2. The combined organics were dried (Na2SO4), concentrated, and purified by column chromatography to yield 25 mg of white solid that was used without further purification. A solution of this solid in 0.4 mL of CH2Cl2 was treated with neat TFA (0.1 mL). After 1 h The mixture was concentrated in vacuo, and the residue was partitioned between EtOAc and saturated aqueous NaHCO3. The organic phase was dried (Na2SO4) and concentrated to yield 19 mg of the title compound that was analytically pure. 1H NMR (300MHz, Acetone-dβ) δ = 8.48 (d, J = 4.1 Hz, 1 H), 7.63 - 7.76 (m, 1 H), 7.52 - 7.61 (m, 1 H), 7.50 (s, 1 H), 7.19 (d, J= 3.4 Hz, 1 H), 7.00 (t, J= 53.9 Hz, 1 H), 6.91 - 7.00 (m, 3 H), 6.46 (br. s., 1 H), 2.05 (s, 3 H); MS m/e 407 (M+H).
Example 31: [4-Amino-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-6-yl]- pyridin-2-yl-methanol
Figure imgf000052_0001
The title compound was prepared using pyridine-2-carbaldehyde in place of 3-fluoro- pyridine-2-carbaldehyde as described in Example 23. 1H NMR (300MHz, Acetone-dβ) δ = 8.56 (d, J= 3.8 Hz, 1 H), 7.75 - 7.90 (m, 1 H), 7.65 (d, J= 7.9 Hz, 1 H), 7.46 (s, 1 H), 7.32 (dd, J= 4.9, 7.5 Hz, 1 H), 7.10 - 7.20 (m, 1 H), 7.00 (t, J= 53.5 Hz, 1 H), 6.90 - 7.00 (m, 3 H), 6.11 (s, 1 H), 5.87 (br. s., 1 H); MS m/e 375 (M+H).
Example 32: [4- Amino-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6-yl] - (3-bromo-pyridin-2-yl)-methanol
Figure imgf000052_0002
The title compound was prepared using 3-bromo-pyridine-2-carbaldehyde in place of 3- fluoro-pyridine-2-carbaldehyde as described in Example 23. 1H NMR (300MHz, MeOD- d4) δ = 8.81 (m, 1 H), 8.52 - 8.72 (m, 1 H), 7.63 - 7.92 (m, 2 H), 7.46 - 7.63 (m, 1 H), 7.05 (m, 1 H), 6.92 (t, J= 53.7 Hz, 1 H), 6.63 (br. s., 1 H); MS m/e 453/455 (M+H).
Example 33: 6-(3-Bromo-pyridin-2-ylmethyl)-2-(5-difluoromethyl-furan-2-yl)- thieno [2,3-d] pyrimidin-4-ylamine
Figure imgf000053_0001
The title compound was prepared using [6-[(3-bromo-pyridin-2-yl)-hydroxy-methyl]-2- (5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 32) in place of {2-(5-difluoromethyl-furan-2- yl)-6-[(3-fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl}-bis- carbamic acid tert-butyl ester as described in Example 24. 1H NMR (300MHz, Acetone- d6) δ = 8.50 - 8.61 (m, 1 H), 7.97 - 8.08 (m, 1 H), 7.31 - 7.33 (m, 1 H), 7.27 (dd, J= 4.7, 8.1 Hz, 1 H), 7.11 - 7.21 (m, 1 H), 7.00 (t, J = 53.9 Hz, 1 H), 6.92 - 6.97 (m, 3 H), 4.56 (s, 2 H); MS m/e 437/439 (M+H).
Example 34: 2-{[4-Amino-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6- yl]-hydroxy-methyl}-pyridin-3-ol
Figure imgf000053_0002
The title compound was prepared using 3-hydroxy-pyridine-2-carbaldehyde in place of 3- fluoro-pyridine-2-carbaldehyde as described in example 23. 1H NMR (300MHz, Acetone-de) δ = 8.09 - 8.17 (m, 1 H), 7.41 (s, 1 H), 7.21 - 7.36 (m, 2 H), 7.18 (d, J= 3.4 Hz, 1 H), 6.99 (t, J = 53.9 Hz, 1 H), 6.87 - 6.98 (m, 2 H), 6.25 (s, 1 H); MS m/e 391 (M+H).
Example 35: 2-(5-Difluoromethyl-furan-2-yl)-6-pyridin-2-ylmethyl-thieno [2,3- d] pyrimidin-4-ylamine
Figure imgf000054_0001
The title compound was prepared using [2-(5-difluoromethyl-furan-2-yl)-6-(hydroxy- pyridin-2-yl-methyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 31) in place of {2-(5-difluoromethyl-furan-2-yl)-6-[(3- fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl}-bis-carbamic acid tert-butyl ester as described in Example 24. 1H NMR (300MHz, MeOD-d4) δ = 8.86 (d, J = 5.7 Hz, 1 H), 8.54 - 8.69 (m, 1 H), 7.96 - 8.13 (m, 2 H), 7.53 - 7.68 (m, 2 H), 7.04 - 7.13 (m, 1 H), 6.97 (t, J= 53.6 Hz, 1 H), 4.84 (s, 2 H); MS m/e 359 (M+H).
Example 36: l-[4-Amino-2-(5-difluoromethyl-furan-2-yl)-thieno[2,3-d]pyrimidin-6- yl]-l-pyridin-2-yl-ethanol
Example 36: step a
[2-(5-Difluoromethyl-furan-2-yl)-6-(pyridine-2-carbonyl)-thieno[2,3-d]pyrimidin-4- yl]-bis-carbamic acid tert-butyl ester
Figure imgf000054_0002
The title compound was prepared using [2-(5-difluoromethyl-furan-2-yl)-6-(hydroxy- pyridin-2-yl-methyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 31) in place of {2-(5-difluoromethyl-furan-2-yl)-6-[(3- fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl}-bis-carbamic acid tert-butyl ester as described in Example 25.
Example 36: step b
1- [4-Amino-2-(5-difluoromethyl-furan-2-yl)-thieno [2,3-d] pyrimidin-6-yl] -1-pyridin-
2-yl-ethanol
Figure imgf000055_0001
The title compound was prepared using [2-(5-difluoromethyl-furan-2-yl)-6-(pyridine-2- carbonyl)-thieno[2,3-d]pyrimidin-4-yl]-bis-carbamic acid tert-butyl ester in place of [2- (5-difluoromethyl-furan-2-yl)-6-(3-fluoro-pyridine-2-carbonyl)-thieno[2,3-d]pyrimidin- 4-yl]-bis-carbamic acid tert-butyl ester as described in Example 30. 1H NMR (300MHz, Acetone-de) δ = 8.52 (d, J= 4.5 Hz, 1 H), 7.79 (t, J= 7.5 Hz, 1 H), 7.71 (d, J= 7.9 Hz, 1 H), 7.48 (s, 1 H), 7.27 (t, J= 6.0 Hz, 1 H), 7.15 (d, J= 3.4 Hz, 1 H), 6.96 (t, J= 53.5 Hz, 1 H), 6.90 - 6.96 (m, 3 H), 1.99 (s, 3 H); MS m/e 389 (M+H).
Example 37: 2-(5-Difluoromethyl-furan-2-yl)-6-(3-methoxy-pyridin-2-ylmethyl)- thieno [2,3-d] pyrimidin-4-ylamine
Figure imgf000055_0002
The title compound was prepared using {2-(5-difluoromethyl-furan-2-yl)-6-[hydroxy-(3- methoxy-pyridin-2-yl)-methyl]-thieno[2,3-d]pyrimidin-4-yl} -bis-carbamic acid tert-butyl ester (an intermediate prepared in Example 29) in place of {2-(5-difluoromethyl-furan-2- yl)-6-[(3-fluoro-pyridin-2-yl)-hydroxy-methyl]-thieno[2,3-d]pyrimidin-4-yl} -bis- carbamic acid tert-butyl ester as described in Example 24. 1H NMR (300MHz, MeOD- d4) δ = 8.42 (d, J = 4.5 Hz, 1 H), 8.31 - 8.34 (m, 1 H), 7.95 - 8.12 (m, 1 H), 7.50 - 7.70 (m, 2 H), 7.05 - 7.13 (m, 1 H), 6.97 (t, J= 53.3 Hz, 1 H), 4.74 (s, 2 H), 4.16 (s, 3 H); MS m/e 389 (M+H)
Biological Assays and Activity
Ligand Binding Assay for Adenosine A2a Receptor (A2A-B)
Ligand binding assay of adenosine A2a receptor was performed using plasma membrane of HEK293 cells containing human A2a adenosine receptor (PerkinElmer, RB-HA2a) and radioligand [3H]CGS21680 (PerkinElmer, NET 1021). Assay was set up in 96-well polypropylene plate in total volume of 200 μL by sequentially adding 20 μLl :20 diluted membrane, 130 μLassay buffer (50 mM Tris-HCl, pH7.4 10 mM MgCl2, 1 mM EDTA) containing [3H] CGS21680, 50 μL diluted compound (4X) or vehicle control in assay buffer. Nonspecific binding was determined by 80 mM NECA. Reaction was carried out at room temperature for 2 hours before filtering through 96-well GF/C filter plate pre-soaked in 50 mM TrisΗCl, pH7.4 containing 0.3% polyethylenimine. Plates were then washed 5 times with cold 50 mM TrisΗCl, pH7.4, dried and sealed at the bottom. Microscintillation fluid 30 μL was added to each well and the top sealed. Plates were counted on Packard Topcount for [3H]. Data was analyzed in Microsoft Excel and GraphPad Prism programs. (Varani, K.; Gessi, S.; Dalpiaz, A.; Borea, P.A. British Journal of Pharmacology, 1996, 117, 1693)
Adenosine A2a Receptor Functional Assay (A2A GAL2]_
To initiate the functional assay, cryopreserved CHO-Kl cells overexpressing the human adenosine A2a receptor and containing a cAMP inducible beta-galactosidase reporter gene were thawed, centrifuged, DMSO containing media removed, and then seeded with fresh culture media into clear 384-well tissue culture treated plates (BD #353961) at a concentration of 1OK cells/well. Prior to assay, these plates were cultured for two days at 370C, 5% CO2, 90% Rh. On the day of the functional assay, culture media was removed and replaced with 45uL assay medium (Hams/F-12 Modified (Mediatech # 10-080CV) supplemented w/ 0.1% BSA). Test compounds were diluted and 11 point curves created at a 100Ox concentration in 100% DMSO. Immediately after addition of assay media to the cell plates, 5OnL of the appropriate test compound antagonist or agonist control curves were added to cell plates using a Cartesian Hummingbird. Compound curves were allowed to incubate at room temperature on cell plates for approximately 15 minutes before addition of a 15nM NECA (Sigma E2387) agonist challenge (5uL volume). A control curve of NECA, a DMSO/Media control, and a single dose of Forskolin (Sigma F3917) were also included on each plate. After additions, cell plates were allowed to incubate at 370C, 5% CO2, 90% Rh for 5.5 - 6 hours. After incubation, media was removed, and cell plates were washed Ix 5OuL with DPBS w/o Ca & Mg (Mediatech 21-031-CV). Into dry wells, 2OuL of Ix Reporter Lysis Buffer (Promega E3971 (diluted in dH2O from 5x stock)) was added to each well and plates frozen at - 200C overnight. For β-galactosidase enzyme colorimetric assay, plates were thawed out at room temperature and 20 μL 2X assay buffer (Promega) was added to each well. Color was allowed to develop at 370C, 5% CO2, 90% Rh for 1 - 1.5 h or until reasonable signal appeared. The colorimetric reaction was stopped with the addition of 60 μL/well IM sodium carbonate. Plates were counted at 405 nm on a SpectraMax Microplate Reader (Molecular Devices). Data was analyzed in Microsoft Excel and IC/EC50 curves were fit using a standardized macro.
Adenosine Al Receptor Functional Assay (A 1GAL2I
To initiate the functional assay, cryopreserved CHO-Kl cells overexpressing the human adenosine Al receptor and containing a cAMP inducible beta-galactosidase reporter gene were thawed, centrifuged, DMSO containing media removed, and then seeded with fresh culture media into clear 384-well tissue culture treated plates (BD #353961) at a concentration of 1OK cells/well. Prior to assay, these plates were cultured for two days at 370C, 5% CO2, 90% Rh. On the day of the functional assay, culture media was removed and replaced with 45uL assay medium (Hams/F-12 Modified (Mediatech # 10-080CV) supplemented w/ 0.1% BSA). Test compounds were diluted and 11 point curves created at a 100Ox concentration in 100% DMSO. Immediately after addition of assay media to the cell plates, 5OnL of the appropriate test compound antagonist or agonist control curves were added to cell plates using a Cartesian Hummingbird. Compound curves were allowed to incubate at room temperature on cell plates for approximately 15 minutes before addition of a 4nM r-PIA (Sigma P4532)/luM Forskolin (Sigma F3917) agonist challenge (5uL volume). A control curve of r-PIA in IuM Forskolin, a DMSO/Media control, and a single dose of Forskolin were also included on each plate. After additions, cell plates were allowed to incubate at 370C, 5% CO2, 90% Rh for 5.5 - 6 hours. After incubation, media was removed, and cell plates were washed Ix 5OuL with DPBS w/o Ca & Mg (Mediatech 21-031-CV). Into dry wells, 2OuL of Ix Reporter Lysis Buffer (Promega E3971 (diluted in dH2O from 5x stock)) was added to each well and plates frozen at -200C overnight. For β-galactosidase enzyme colorimetric assay, plates were thawed out at room temperature and 20 μL 2X assay buffer (Promega) was added to each well. Color was allowed to develop at 37 0C, 5% CO2, 90% Rh for 1 - 1.5 h or until reasonable signal appeared. The colorimetric reaction was stopped with the addition of 60 μL/well IM sodium carbonate. Plates were counted at 405 nm on a SpectraMax Microplate Reader (Molecular Devices). Data was analyzed in Microsoft Excel and IC/EC50 curves were fit using a standardized macro.
A2a ASSAY DATA
Figure imgf000058_0001
Figure imgf000059_0001
ND indicates that no data was available.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.
All publications disclosed in the above specification are hereby incorporated by reference in full.

Claims

WE CLAIM:
1. A compound of Formula Z
Figure imgf000060_0001
wherein
X is selected from the group consisting of
Figure imgf000060_0002
R1 is heteroaryl which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C(i_4)alkyl, CHF2, CF3, OCF3, cyclopropyl, and OC(i_
4)alkyl;
R2 is heteroaryl wherein said heteroaryl is optionally substituted with Cl, F, Br, OC(i_
4)alkyl, OCF3, OH, C(i_4)alkyl, CHF2, CF3, OCH2CF3, or a ring selected from the group consisting of:
Figure imgf000060_0003
wherein Ra, Rb, and Rc are independently H or C(i_4)alkyl; Rd is H, -C(i.4)alkyl, -CH2CH2OCH2CH2OCH3, -CH2CO2H, - C(O)C(i_4)alkyl, or -CH2C(O)C(M)alkyl; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
2. A compound of Claim 1, wherein:
R1 is furyl, oxazolyl, thiazolyl, pyridyl, pyrimadyl, isoxazolyl, pyrrolyl, imidazoyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C(1-4)alkyl, CHF2, CF3, cyclopropyl, and OC(i_4)alkyl; R2 is pyrimadyl, isoxazolyl, pyrrolyl, imidazoyl, furyl, oxazolyl, pyridyl or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, C(M)alkyl, CHF2, CF3, and OC(i_4)alkyl; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
3. A compound of Claim 2, wherein:
X is selected from the group consisting of
Figure imgf000061_0001
R1 is furyl, oxazolyl, thiazolyl, pyridyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, CN, C(i_4)alkyl,
CHF2, CF3, cyclopropyl, and OC(i_4)alkyl;
R2 is pyridyl or pyridazyl, either of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, C(i_4)alkyl, CHF2, CF3, and OC(i_
4)alkyl; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
4. A compound of Claim 3, wherein:
R1 is furyl, oxazolyl, thiazolyl, pyridyl, or pyridazyl, any of which may be substituted with one substituent selected from the group consisting of CN, CH3, CHF2, cyclopropyl, and OCH3;
R2 is pyridyl or pyridazyl, either of which may be substituted with one substituent selected from the group consisting of Cl, Br, F, OH, and OCH3; and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
5. A compound of Claim 4, wherein:
R1 is selected from the group consisting of:
Figure imgf000062_0001
Figure imgf000062_0002
R2 is selected from the group consisting of:
Figure imgf000062_0003
and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof.
6. A compound selected from the group consisting of:
Figure imgf000062_0004
Figure imgf000063_0001
Figure imgf000064_0001
63
Figure imgf000065_0001
Figure imgf000066_0001
65
Figure imgf000067_0001
and solvates, hydrates, tautomers, and pharmaceutically accceptable salts thereof.
7. A pharmaceutical composition comprising the compound of Claim 1; and a pharmaceutically acceptable carrier.
8. A method of treating a subject having a disorder ameliorated by antagonizing Adenosine A2a receptors in appropriate cells in the subject, which comprises administering to the subject a therapeutically effective dose of the compound of Claim 1.
9. A method of preventing a disorder ameliorated by antagonizing Adenosine A2a receptors in appropriate cells in the subject, comprising administering to the subject a prophylactically effective dose of the compound of Claim 1 either preceding or subsequent to an event anticipated to cause a disorder ameliorated by antagonizing Adenosine A2a receptors in appropriate cells in the subject.
10. The method of Claim 8, comprising administering to the subject a therapeutically or prophylactically effective dose of the pharmaceutical composition of Claim 7.
11. The method of Claim 9, comprising administering to the subject a therapeutically or prophylactically effective dose of the pharmaceutical composition of Claim 7.
12. The method of Claim 8, wherein the disorder is a neurodegenerative disorder or a movement disorder.
13. The method of Claim 8, wherein the disorder is selected from the group consisting of Parkinson's Disease, Huntington's Disease, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer's Disease, and Senile Dementia.
14. The method of Claim 9, wherein the disorder is a neurodegenerative disorder or a movement disorder.
15. The method of Claim 9, wherein the disorder is selected from the group consisting of Parkinson's Disease, Huntington's Disease, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer's Disease, and Senile Dementia.
16. The method of Claim 8, wherein the disorder is Parkinson's Disease.
17. The method of Claim 8, wherein the disorder is addiction.
18. The method of Claim 8, wherein the disorder is Attention Deficit Hyperactivity Disorder (ADHD).
19. The method of Claim 8, wherein the disorder is depression.
20. The method of Claim 8, wherein the disorder is anxiety.
PCT/US2009/058731 2008-10-13 2009-09-29 Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists Ceased WO2010045015A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2740413A CA2740413A1 (en) 2008-10-13 2009-09-29 Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists
MX2011003966A MX2011003966A (en) 2008-10-13 2009-09-29 Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10479108P 2008-10-13 2008-10-13
US61/104,791 2008-10-13
US12/499,370 2009-07-08
US12/499,370 US20100093756A1 (en) 2008-10-13 2009-07-08 HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
WO2010045015A1 true WO2010045015A1 (en) 2010-04-22

Family

ID=42099440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058731 Ceased WO2010045015A1 (en) 2008-10-13 2009-09-29 Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists

Country Status (4)

Country Link
US (1) US20100093756A1 (en)
CA (1) CA2740413A1 (en)
MX (1) MX2011003966A (en)
WO (1) WO2010045015A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
RU2803136C2 (en) * 2017-07-17 2023-09-07 Сейнт Луис Юниверсити THIENO[2,3-d]PYRIMIDINES AS ANTIMICROBIAL AGENTS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048164A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Adenosine a2a receptor antagonists
WO2009111449A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048164A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Adenosine a2a receptor antagonists
WO2009111449A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUZLENKO, O. ET AL.: "Potent Adenosine A1 and A2a Receptors Antagonists: Recent Developments", CURRENT MEDICINAL CHEMISTRY, vol. 13, 2006, pages 3609 - 3625, XP002559034 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
RU2803136C2 (en) * 2017-07-17 2023-09-07 Сейнт Луис Юниверсити THIENO[2,3-d]PYRIMIDINES AS ANTIMICROBIAL AGENTS

Also Published As

Publication number Publication date
CA2740413A1 (en) 2010-04-22
US20100093756A1 (en) 2010-04-15
MX2011003966A (en) 2011-05-23

Similar Documents

Publication Publication Date Title
EP1107973B1 (en) NOVEL THIENO[2,3-d]PYRIMIDINEDIONES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THERAPY
WO2007011284A1 (en) Therapeutic agents
AU2009303694A1 (en) Methylene amines of thieno (2,3-d) pyrimidine and their use as adenosine A2a receptor antagonists
WO2006014647A2 (en) Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
US20100093764A1 (en) AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP1963337B1 (en) THIENO[2,3-b]PYRIDINE DERIVATIVES
WO2010045008A1 (en) AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2010045015A1 (en) Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists
WO2010045009A1 (en) PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d] PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2010045016A1 (en) Heterocyclyl and cycloalkyl substituted thieno [2,3-d] pyrimidine and their use as adenosine a2a receptor antagonists
WO2010045012A1 (en) Heteroaryl and phenyl substituted thieno [2,3-d] pyrimidines and their use as adenosine a2a receptor antagonists
EP4514808B1 (en) Compositions useful for modulating splicing
US20100093763A1 (en) PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
AU2010313574A1 (en) 2-amino-9-[4-(4-methoxy-phenoxy) - piperid in -1-yl] -4-phenyl-indeno [1,2-d] pyrimidin -5 -one and its use as a highly selective adenosine A2A receptor antagonist
HK1166073A1 (en) Thienopyrimidinedione derivatives as trpa1 modulators
HK1166073B (en) Thienopyrimidinedione derivatives as trpa1 modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09740566

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2740413

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011532135

Country of ref document: JP

Ref document number: MX/A/2011/003966

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009740566

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP